CN103553996B - Anticholinergic pharmaceutical composition - Google Patents

Anticholinergic pharmaceutical composition Download PDF

Info

Publication number
CN103553996B
CN103553996B CN201310571655.XA CN201310571655A CN103553996B CN 103553996 B CN103553996 B CN 103553996B CN 201310571655 A CN201310571655 A CN 201310571655A CN 103553996 B CN103553996 B CN 103553996B
Authority
CN
China
Prior art keywords
impurity
glycopyrronium bromide
content
present
bulk drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310571655.XA
Other languages
Chinese (zh)
Other versions
CN103553996A (en
Inventor
李兴惠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunan Dongting Pharmaceutical Co Ltd
Original Assignee
Beijing Sanquan Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Sanquan Pharmaceutical Technology Co ltd filed Critical Beijing Sanquan Pharmaceutical Technology Co ltd
Priority to CN201510727148.XA priority Critical patent/CN105175304A/en
Priority to CN201310571655.XA priority patent/CN103553996B/en
Publication of CN103553996A publication Critical patent/CN103553996A/en
Application granted granted Critical
Publication of CN103553996B publication Critical patent/CN103553996B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention relates to Anticholinergic pharmaceutical composition.Specifically, the present invention relates to a kind of medicine that can be used for pharmacy, wherein comprise following formula: compound.Present invention also offers the preparation of this medicine, they can be used for anesthesia, peptide ulceration, salivation etc. clinically as a kind of anticholinergic.This bulk drug or preparation have suppression gastric secretion and regulate gastrointestinal peristalsis effect; There is the anti-salivation effect stronger than coromegine, but do not have central cholinolytic active.Be generally used for the diseases such as gastric and duodenal ulcer, chronic gastritis, gastroxia clinically.

Description

Anticholinergic pharmaceutical composition
Technical field
The invention belongs to medical art, relate to a kind of pharmaceutical composition as cholilytic drug, particularly relate to a kind of pharmaceutical composition comprising Glycopyrronium Bromide as cholilytic drug.
Background technology
Glycopyrronium Bromide; its English GlycopyrroniumBromide or Glycopyrrolate by name; its typical chinesization formal name used at school is: (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxyl-2-phenyl acetyl) oxygen base]-1; 1-dimethyipyrrolidinium bromide; typical English language Chemical is called: (3RS)-3-[(2SR)-(2-Cyclopentyl-2-hydroxy-2-phenylacetyl) oxy]-1; 1-dimethylpyrrolidiniumbromide, its molecular formula is C 19h 28brNO 3, molecular weight is 398.3, and its typical chemical structural formula is:
Namely; (3R)-3-[(2S)-(2-cyclopentyl-2-hydroxyl-2-phenyl acetyl) oxygen base]-1 as medicinal Glycopyrronium Bromide; 1-dimethyipyrrolidinium bromide and (3S)-3-[(2R)-(2-cyclopentyl-2-hydroxyl-2-phenyl acetyl) oxygen base]-1,1-dimethyipyrrolidinium bromide one group of enantiomorph.
Glycopyrronium Bromide is white or almost white crystalline powder, and soluble in water, methyl alcohol, ethanol are almost insoluble in trichloromethane or ether.
CN101133021A (Chinese Patent Application No. 200680006901.5, Suo Sai, Authorization Notice No. CN101133021B) discloses crystallization and the purification process of Glycopyrronium Bromide.Comprise the grand amine alkali of lattice and monobromethane reaction in a solvent, wherein select described solvent so that diastereomer R in the diastereomer of described product, the ratio of S and S, R is relative to diastereomer R, and the ratio of R and S, S is preponderated.And the diastereomer desired by being separated by one or more crystallization control step.From this patent documentation, at the later stage of preparation, reacted with monobromethane in suitable solvent by grand for lattice amine alkali (can referred to as GP alkali or GP alkali impurity), obtain Glycopyrronium Bromide, elementary operation process is:
What the present invention relates to is as medicinal Glycopyrronium Bromide, when describing together with its enantiomeric impurity and being convenient to distinguish, the present invention also can be described as 3R2S/3S2R Glycopyrronium Bromide as medicinal Glycopyrronium Bromide, and its a pair enantiomeric impurity existed in addition can be described as 3S2R/3S2S impurity or 3S2R/3S2S Glycopyrronium Bromide or other similar appellation, as described in CN101133021B specification sheets [0032] section, that the present invention relates to is R as medicinal substance, S/S, R Glycopyrronium Bromide, and be that two configurations are respectively R with relative, R and S, the impurity of S, they in the present invention can referred to as R, R/S, S impurity or be called erythro isomer or be called R, R/S, S Glycopyrronium Bromide.Described R; R/S; S impurity or be called that erythro isomer namely: (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxyl-2-phenyl acetyl) oxygen base]-1; 1-dimethyipyrrolidinium bromide; English name (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl) oxy]-1; 1-dimethylpyrrolidiniumbromide, chemical structural formula is:
Outside R, R/S, S impurity, according to the preparation method of above-mentioned CN101133021A and other document, also the GP alkali impurity of trace may be had by remnants as in medicinal Glycopyrronium Bromide.
Such as, CN103159659A (Chinese Patent Application No. 201110426038.1, Shenyang medicine section) disclose the preparation method of muscarinic receptor antagonist glycopyrronium bromide, it is characterized in that: benzoylformic acid obtains α-cyclopentyl methyl mandelate through grignard reaction, esterification, then obtain Glycopyrronium Bromide with N-methylpyrrolidin-3-alcohol through transesterify, quaterisation.
And such as, CN102627595A (Chinese Patent Application No. 201210069208.X, Xu Kui) disclose the preparation method of Glycopyrronium Bromide, more particularly, relate to enrichment high purity (3R, 2 ' S) and (3S, 2 ' R) Glycopyrronium Bromide and synthetic method in relate to the preparation method of new intermediate.It is believed that this invention overcome prior art exist yield low, pollute the defects such as large, provide that a kind of yield is high, environmental pollution is little, the preparation method of the Glycopyrronium Bromide of the preparation formula of simple purification (I), Glycopyrronium Bromide fusing point prepared by the method is 195 DEG C ~ 198 DEG C.
As a kind of anticholinergic, can be used for anesthesia, peptide ulceration, salivation disease etc. clinically.Glycopyrronium Bromide is quaternary amines anticholinergic drug, has and suppresses gastric secretion and regulate gastrointestinal peristalsis effect; This product also has the anti-salivation effect stronger than coromegine, but does not have central cholinolytic active.Be generally used for the diseases such as gastric and duodenal ulcer, chronic gastritis, gastroxia clinically.Curative effect and propantheline similar or exceed.Quiet note or intramuscular injection can be used for preanesthetic medication, to suppress glandular secretion, act on sustainable about 7 hours.Consumption usage: oral, each 1 ~ 2mg, 3 ~ 4 times on the 1st, takes after meal and before sleeping; The each 1mg of maintenance dose, every day 2 times; 1 maximum dose is 4mg, and maximum dose on the 1st is 12mg; Preanesthetic medication, quiet note or intramuscular injection 0.2 ~ 0.4mg.Spendable formulation has its tablet (0.5mg/ sheet, 1mg/ sheet), oral liquid, injection liquid (0.2mg/mL) etc. clinically.
The safe, effective, controlled of streat drug is that industry is very paid close attention to.Even if be successfully applied to clinical, those skilled in the art are still expected for Glycopyrronium Bromide and provide a kind of medicament production such as pharmaceutical preparation with Good Pharmacy performance.
Summary of the invention
The present inventor has been found that, use specific treatment process effectively can reduce R in Glycopyrronium Bromide simultaneously, R/S, the content of S impurity and GP alkali impurity, and display has the medicinal Glycopyrronium Bromide of low impurity and the formulation example of preparation such as its injection liquid shows the such as security of beat all pharmaceutical properties such as stability and/or biological property.Therefore the present invention finds and is able to and completes.
For this reason, first aspect present invention provides a kind of preparation method of bulk drug of hyoscine, and the activeconstituents of this bulk drug is Glycopyrronium Bromide, and the method comprises with an organic solvent to the step that the bulk drug comprising Glycopyrronium Bromide is refined.
In the present invention, term Glycopyrronium Bromide is compounds of Formula I:
(formula I)
And enantiomorph.
In the methods of the invention, in above-mentioned " step to the bulk drug comprising Glycopyrronium Bromide is refined ", described term " comprises the bulk drug of Glycopyrronium Bromide ", and it can be crude starting material medicine or crude product, it can be such as the conventionally bulk drug for preparing of method, although the bulk drug that art methods prepares may be used for the preparation of formulation example as injection liquid equally, but processed further by the bulk drug of the inventive method to the prior art, more excellent performance is given with the preparation making it and be prepared into by it, such as better stability, better security.
" bulk drug of hyoscine " of the present invention or " bulk drug " its can be used as the bulk drug of pharmaceutical composition such as pharmaceutical preparation production, therefore it also can be regarded as the bulk drug of formula I and enantiomorph and Glycopyrronium Bromide.Well-known, as the bulk drug of the hyoscine of useful in preparing drug formulations, they comprise formula I as main ingredient and enantiomorph thereof, can also comprise the trace impurity of the limit that conforms with the regulations.
Method according to a first aspect of the present invention, it comprises and carries out recrystallization to reach the step of refining object to the bulk drug comprising Glycopyrronium Bromide.
Method according to a first aspect of the present invention, described recrystallization is dissolved in by bulk drug in the first solvent, then in this solution, adds the second solvent, be settled out crystallization to make Glycopyrronium Bromide from solvent.
Method according to a first aspect of the present invention, described first solvent is selected from: water, methyl alcohol, ethanol, 1-octanol, phenylcarbinol, methyl-sulphoxide, methylene dichloride, ethyl acetate and combination thereof.In one embodiment, described first solvent is selected from: ethanol, 1-octanol, methyl-sulphoxide, methylene dichloride, ethyl acetate and combination thereof.In one embodiment, described first solvent is the mixture of ethanol and ethyl acetate.In one embodiment, described first solvent is the mixture of ethanol and ethyl acetate volume ratio 100:7 ~ 20, preferably the mixture of ethanol and ethyl acetate volume ratio 100:10 ~ 16.In the present invention, if not otherwise indicated, the ethanol mentioned is dehydrated alcohol.
Method according to a first aspect of the present invention, described second solvent is selected from: ether, methyl ethyl ether, t-butyl methyl ether, normal heptane, normal hexane, Skellysolve A and combination thereof.In one embodiment, described second solvent is selected from: ether, methyl ethyl ether, t-butyl methyl ether and combination thereof.In one embodiment, described second solvent is methyl ethyl ether.
Method according to a first aspect of the present invention, the volume ratio of described first solvent and the second solvent is 1:7 ~ 25, such as 1:10 ~ 20, such as 1:10 ~ 15.
Method according to a first aspect of the present invention, wherein said recrystallization carries out according to the general operation method of those skilled in the art, particularly in the temperature range of comparatively high temps such as more than 40 ° until below solvent reflux temperature (such as at the temperature of 55 ~ 60 DEG C) by solute dissolves in solvent, then such as within the scope of 0 ~ 10 °, material crystallization is made at a lower temperature, then crystallization is leached, drying, to obtain bulk drug of the present invention.Repeatedly recrystallization can be carried out as required.
Method according to a first aspect of the present invention, when bulk drug being dissolved in the first solvent, it is more low better that those skilled in the art understand now solvent for use amount usually, as long as normally reach the volume of a little higher than meltage, such as reach the solvent volume of 2 ~ 4 times of meltages, to create conditions for later crystallization and aftertreatment.Therefore special stipulation need not be done to this first solvent load in the present invention.But in order to obtain good separating effect, in one embodiment of the invention, the ratio that bulk drug can be made to be dissolved in the first solvent with the concentration of 0.1 ~ 0.5g/ml (such as 0.1 ~ 0.2g/ml) processes.
Have been found that and use crystallization method of the present invention effectively can remove erythro isomer impurity and GP alkali impurity simultaneously.
In the present invention, erythro isomer refers to following formula Ix compound
(formula Ix)
And enantiomorph.It is optionally present in bulk drug of the present invention or preparation as impurity.It also can be described as impurity Ix or Ix impurity or Ix or other similar appellation (mixture for formula Ix compound and enantiomorph thereof) in the present invention.
In the present invention, the grand amine alkali of lattice (can referred to as GP alkali or GP alkali impurity) refers to following formula Iy compound
(formula Iy), it is optionally present in bulk drug of the present invention or preparation as impurity.It also can be described as impurity Iy or Iy impurity or Iy or other similar appellation in the present invention.
In the present invention, with following formula Iz compound
(formula Iz), it is optionally present in bulk drug of the present invention or preparation as impurity.It also can be described as impurity Iz or Iz impurity or Iz or other similar appellation in the present invention.
Method according to a first aspect of the present invention, bulk drug obtained by it comprises the Glycopyrronium Bromide as main ingredient, and the optional erythro isomer as impurity, erythro isomer for Glycopyrronium Bromide content lower than 0.5% (such as lower than 0.4%, such as, lower than 0.3%).
In bulk drug of the present invention (wherein comprising as the formula I of activeconstituents and enantiomorph thereof and Glycopyrronium Bromide), the content of erythro isomer impurity is with itself weight percent gauge relative to Glycopyrronium Bromide, that is: for certain a collection of bulk drug of the present invention or with the material of its pharmaceutical composition such as preparation made for raw material, when calculating the content of wherein impurity erythro isomer, can calculate with following formula:
Impurity erythro isomer content (%)=(in this material impurity erythro isomer this material of quality ÷ in the quality of Glycopyrronium Bromide) × 100%
According to above definition, above-mentioned material both can be take formula I and enantiomorph thereof as the bulk drug of main composition, can also be added with the pharmaceutical composition of other pharmaceutical excipient, such as pharmaceutical preparation, such as injection liquid with formula I and enantiomorph thereof for activeconstituents.Thus, the calculating of impurity erythro isomer content can not be affected because of the existence of other composition such as pharmaceutical excipient.During the calculating of other impurity that the present invention relates to such as impurity Iy and impurity Iz and other impurity, also process in the same manner.[HPLC-A] and [HPLC-B] is although measure and calculate erythro isomer, impurity Iy, impurity Iz and other impurity phase for being compare calculating by the concentration of the two in need testing solution in the content of Glycopyrronium Bromide below, because when preparing need testing solution, impurity is identical with the extension rate of Glycopyrronium Bromide or can determine, therefore this concentration compares with the quality comparation in above formula is identical in itself.
In the present invention, the method measuring impurity Ix content can have many, such as, according to well known to a person skilled in the art the measuring method that mode is determined.A kind of typical method is high performance liquid chromatography.In addition, can be separated by preparative high performance liquid chromatography and obtain impurity reference substance (the such as impurity Ix that highly purified such as chromatographic purity reaches more than 98%, and such as impurity Iy mentioned below and impurity Iz), with this impurity reference substance for contrast, the relative content of those impurity in the bulk drug measuring the contained I of the present invention and enantiomorph thereof by the known feasible method of those skilled in the art and the pharmaceutical preparation prepared by them.The impurity that the present invention relates to comprises impurity Ix, impurity Iy and impurity Iz etc., and they are all that prior art is known or prepare by art methods, and can buy from commercial channels, such as, can order from Sigma-Aldrich company and obtain.In the present invention, as α-cyclopentyl amygdalic acid that impurity Iz is the article No. 706396 buied from Sigma-Aldrich company, purity is more than 98%, use as chemical test of the present invention or biological test, it is chromatographic purity 99.1% in the present invention [HPLC-B] method, and in this chromatography relative to the relative retention time of 3R2S/3S2R Glycopyrronium Bromide of the present invention in 2.67 ~ 2.69 scopes.
A kind of typical high performance liquid chromatography is high performance liquid chromatography A (can be called for short [HPLC-A] in the present invention) hereinafter described, its to can be used for measuring in the various material of the present invention (comprising bulk drug and preparation) various impurity particularly impurity Ix in this material relative to the amount of Glycopyrronium Bromide.Certainly, it will be appreciated by those skilled in the art that analytical procedure is easily improved, anyly available all can be used for the present invention with the method for the various impurity in the potential various material of mensuration the present invention; In view of the content of the various impurity in the various material of the present invention can not change because of improving of analytical procedure, the foreign matter content therefore in the various material of the present invention or the measuring method of relative content can be not particularly limited.Certainly, in the present invention, if not otherwise indicated, particularly the content of impurity Ix or the method for relative content are all adopt [HPLC-A] described herein to measure various impurity in various material (comprising bulk drug and preparation).
A kind of typical high performance liquid chromatography is high performance liquid chromatography B (can be called for short [HPLC-B] in the present invention) hereinafter described, its to can be used for measuring in the various material of the present invention (comprising bulk drug and preparation) various impurity particularly impurity Iy and/or impurity Iz in this material relative to the amount of Glycopyrronium Bromide.Certainly, it will be appreciated by those skilled in the art that analytical procedure is easily improved, anyly available all can be used for the present invention with the method for the various impurity in the potential various material of mensuration the present invention; In view of the content of the various impurity in the various material of the present invention can not change because of improving of analytical procedure, the foreign matter content therefore in the various material of the present invention or the measuring method of relative content can be not particularly limited.Certainly, in the present invention, if not otherwise indicated, particularly the content of impurity Iy and/or impurity Iz or the method for relative content are all adopt [HPLC-B] described herein to measure various impurity in various material (comprising bulk drug and preparation).
Have been found that along with the prolongation of storage time, impurity Iz content demonstrates the trend gradually increased for the bulk drug of the present invention comprising Glycopyrronium Bromide and formula I and enantiomorph thereof or the pharmaceutical preparation be made up of them.Particularly when impurity Iy content is higher, such as relative to Glycopyrronium Bromide meter impurity Iy content higher than 0.15% (particularly higher than 0.20%, particularly higher than 0.25%, particularly higher than 0.30%, particularly higher than 0.50%) time, show the prolongation along with storage time of bulk drug of the present invention or the pharmaceutical preparation be made up of them, impurity Iz content demonstrates the trend gradually increased.In the present invention, have been surprisingly found that, by the bulk drug of the present invention of the contained I of purifying and enantiomorph thereof, the impurity Iy coming from technique wherein comprised is reduced to a certain degree, particularly make Iy content (relative to Glycopyrronium Bromide meter) lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope) time, these bulk drugs or pharmaceutical preparation gather way at long-time storage rear impurity Iz content and are significantly suppressed, this is completely beat all.
Although the various chemical substances that the present invention relates to, such as formula I and enantiomorph thereof, impurity Ix, impurity Iy, impurity Iz, their chemical structure is known and can directly obtains with commercial sources from the market, but it is as well known to those skilled in the art, these impurity can also come qualitative by the high performance liquid chromatography of regulation or characterize, such as by the high performance liquid chromatography operation of regulation, this impurity is determined by measuring the retention behavior of impurity in this regulation high performance liquid chromatography (i.e. relative retention time, RRT).Particularly, the present invention has been found that, in [HPLC-A] of the present invention system, for formula I, the relative retention time (usual RRT about 0.89) in 0.86 ~ 0.92 scope of impurity Ix, thus this impurity Ix also can be called RRT0.89 impurity, impurity RRT0.89 or RRT0.89 by the present invention.
And in [HPLC-B] of the present invention system, for formula I, the relative retention time (usual RRT about 1.14) in 1.10 ~ 1.18 scopes of impurity Iy, thus this impurity Iy also can be called RRT1.14 impurity, impurity RRT1.14 or RRT1.14 by the present invention.
In addition, in [HPLC-B] of the present invention system, for formula I, the relative retention time (usual RRT about 2.68) in 2.63 ~ 2.73 scopes of impurity Iz, thus this impurity Iz also can be called RRT2.68 impurity, impurity RRT2.68 or RRT2.68 by the present invention.
Therefore, under the invention in literary composition, when mentioning RRT0.89 impurity, all refer to that, in [HPLC-A] system, for the retention time of formula I, relative retention time occurs impurity in 0.86 ~ 0.92 scope, this impurity is impurity Ix; Similarly, in the present invention, when mentioning RRT1.14 impurity, all refer to that, in [HPLC-B] system, for the retention time of formula I, relative retention time occurs impurity in 1.10 ~ 1.18 scopes, this impurity is impurity Iy; Similarly, in the present invention, when mentioning RRT2.68 impurity, all refer to that, in [HPLC-B] system, for the retention time of formula I, relative retention time occurs impurity in 2.63 ~ 2.73 scopes, this impurity is impurity Iz.
The implication of relative retention time is well known in the art, such as, the relative retention time (being abbreviated as RRT) of impurity Ix refers in color atlas, the retention time of impurity Ix chromatographic peak is divided by the value of the retention time gained of formula I chromatographic peak, the i.e. RRT=impurity Ix retention time ÷ formula I retention time of Ix, and the relative retention time of Glycopyrronium Bromide itself is 1 or 1.00, this algorithm well known to a person skilled in the art.
Method according to a first aspect of the present invention, comprises in the bulk drug of the present invention of Glycopyrronium Bromide obtained by it, Ix impurity phase for Glycopyrronium Bromide content lower than 0.5% (such as lower than 0.4%, such as, lower than 0.3%).This content can use high effective liquid chromatography for measuring and calculate, and particularly uses [HPLC-A] measure and calculate.
In the present invention, the measuring method of [HPLC-A] is as follows:
(i) solution:
The biphosphate sodium water solution of buffered soln: 2.8g/L, is adjusted to pH value 6.50 ± 0.05 with 10% sodium hydroxide solution;
Moving phase: methyl alcohol: acetonitrile: volume of buffer solution is than the mixed solution of 50:10:40;
System suitability solution: with the solution of moving phase preparation, the concentration wherein containing erythro isomer reference substance and Glycopyrronium Bromide reference substance is respectively 40 μ g/mL;
Standardized solution A: precision takes Glycopyrronium Bromide reference substance and is about 50mg, is placed in 100ml measuring bottle, dissolves and is diluted to scale, shake up by moving phase, makes the standardized solution A that concentration is about 500 μ g/mL;
[as well known to those skilled in the art, above-mentionedly take Glycopyrronium Bromide reference substance " about 50mg ", actually operating needs modify with " about ", when reason is precision weighing solid materials, such as use ten thousand/balance, usually be difficult to directly claim to obtain 50.00mg, but usually can depart to some extent, such as depart from this numerical value ± 2%, such as precision weighing is to 50.40mg, then depart from 0.8%, but this departing from makes concentration below continue to depart from and is extended in final numerical evaluation, and in final numerical evaluation, consider that this weighing departs from, thus this deviation theory final can not cause miscalculation, thus the statement of " about " herein allows, this is also be all the material taking " about " certain amount usually when carrying out precision weighing in the Chinese Pharmacopoeia of various version.In addition, in one embodiment, the present invention relates to for " about " of modifying a numerical value be defined as allowing departing from its numerical value modified ± 2%, such as above-mentioned " precision takes Glycopyrronium Bromide reference substance and is about 50mg " also can be expressed as " precision takes Glycopyrronium Bromide reference substance 50mg ± 1mg " or other similar statement.Also similar meaning is had] in other similar statement linguistic context of the present invention
Standardized solution B: precision measures the above standardized solution A of 1ml, is placed in 100ml measuring bottle, is diluted to scale by moving phase, shake up, and makes the standardized solution B that concentration is about 5 μ g/mL;
Need testing solution: precision takes the trial-product being about 50mg containing Glycopyrronium Bromide, be placed in 100ml measuring bottle, dissolve by moving phase and be diluted to scale, shake up, filter if desired, make and be about the need testing solution of 500 μ g/mL containing Glycopyrronium Bromide concentration (wherein said trial-product can be the various samples comprising Glycopyrronium Bromide, it can be such as Glycopyrronium Bromide crude product, bulk drug, highly finished product and the preparation be made up of them, need according to concrete mensuration and determine, when measure be preparation time, be converted to the Glycopyrronium Bromide comprised in said preparation appropriate to be mixed with respective concentration---these operative techniquies well known to a person skilled in the art),
(ii) chromatographic system:
Chromatographic run carries out according to Chinese Pharmacopoeia version in 2010 two contained high performance liquid chromatography of annex V D, and chromatographic condition is as follows:
Detector: UV-detector, determined wavelength UV222nm;
Chromatographic column: beta-cyclodextrin bonded silica gel post, filler granularity 5 μm, column internal diameter 4.0mm, column length 25cm; [note: the filler of above-mentioned beta-cyclodextrin bonded silica gel post is a kind of beta-cyclodextrin bound porous silica gel, this type of chromatographic column can easily be buied from the market, it can be such as the Chiradex brand product purchased from MerckKGaA company, can be the YMCCHIRALCDBR β brand product purchased from YMC company, etc.Hereafter use this YMC Products in concrete test]
Column temperature: 30 DEG C;
Flow velocity: 1mL/min;
Sample size: 10 μ L;
System suitability: the resolution in system suitability solution color atlas between erythro isomer and Glycopyrronium Bromide is not less than 1.2, the tail factor is ask to be no more than 2.0 in standardized solution B color atlas, in standardized solution B color atlas, relative standard deviation is no more than 6.0%, is determined retention time and the relative retention time of the two of erythro isomer and Glycopyrronium Bromide by system suitability solution color atlas and standardized solution B;
(iii) measure:
Respectively need testing solution, standardized solution A, standardized solution B injection liquid chromatography are measured, read the peak area of Glycopyrronium Bromide in gained three color atlass, and the peak area (when this chromatographic peak exists) of erythro isomer in need testing solution color atlas, and their retention time;
Press external standard method with the concentration of Glycopyrronium Bromide in calculated by peak area need testing solution according to need testing solution color atlas and standardized solution A color atlas, (unit is μ g/mL to be designated as Ci; The calculating formula that well-known external standard method calculates Ci is: Glycopyrronium Bromide concentration in Ci=(in need testing solution color atlas in main peak area ÷ standardized solution A color atlas main peak area) × standardized solution A; Unit is μ g/mL, the interference such as this despumation of Glycopyrronium Bromide concentration, auxiliary material, moisture, for bulk drug, this concentration may be close with dosing concentration, but the crude product more for impurity and/or moisture etc. and with the addition of auxiliary material pharmaceutical composition such as pharmaceutical preparation for, this concentration can reflect the concentration of Glycopyrronium Bromide in solution exactly);
Be calculated as follows the concentration of erythro isomer in need testing solution (when present), be designated as Cx (unit is μ g/mL):
To be calculated as follows in sample erythro isomer content (being percentage composition, %) for Glycopyrronium Bromide:
Erythro isomer content (%)=(Cx ÷ Ci) × 100%.
Above in [HPLC-A], be 1 or for 1.00 in the relative retention time of Glycopyrronium Bromide, the relative retention time of erythro isomer in 0.86 ~ 0.92 scope, hereafter in concrete measurement result all within the scope of this, be particularly about 0.89.
Method according to a first aspect of the present invention, comprise in the bulk drug of the present invention of Glycopyrronium Bromide obtained by it, Iy impurity phase for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope).This content can use high effective liquid chromatography for measuring and calculate, and particularly uses [HPLC-B] measure and calculate.
Method according to a first aspect of the present invention, comprise in the bulk drug of the present invention of Glycopyrronium Bromide obtained by it, Iz impurity phase for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iz foreign matter content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 0.500% scope (such as in 0.002% ~ 0.400% scope, such as in 0.002% ~ 0.300% scope, such as in 0.002% ~ 0.250% scope, such as in 0.002% ~ 0.200% scope, such as in 0.002% ~ 0.150% scope, such as in 0.002% ~ 0.130% scope).This content can use high effective liquid chromatography for measuring and calculate, and particularly uses [HPLC-B] measure and calculate.
In the present invention, the measuring method of [HPLC-B] is as follows:
(i) solution:
Buffered soln: the 1-sodium hexanesulfonate monohydrate of the anhydrous sodium sulphate of 1.0g and 200mg is dissolved in 650mL water, adds the 1N sulfuric acid of 3.0mL in this solution, mixing, to obtain final product;
Diluting soln: the 1-sodium hexanesulfonate monohydrate of the anhydrous sodium sulphate of 1.0g, 6.8g potassium primary phosphate and 200mg is dissolved in 650mL water, the 1N sulfuric acid of 3.0mL, the methyl alcohol of 150mL and the acetonitrile of 200mL is added in this solution, mixing, is 2.8 by phosphoric acid adjust ph, obtains final product;
Solution A: acetonitrile: methyl alcohol: volume of buffer solution is than the mixed solution of 20:15:65;
Solution B: acetonitrile: methyl alcohol: volume of buffer solution is than the mixed solution of 50:15:35;
Standardized solution A: precision takes Glycopyrronium Bromide reference substance and is about 100mg, is placed in 100ml measuring bottle, dissolves and be diluted to scale with diluting soln, if desired through supersound process to impel dissolving, shaking up, make the solution that concentration is about 1000 μ g/mL, is standardized solution A;
Standardized solution B: precision takes impurity Iy reference substance and each about 15mg of impurity Iz reference substance respectively, be placed in 100ml measuring bottle, the above standardized solution A that another precision measures 15ml is placed in same measuring bottle, add diluting soln and be diluted to scale, if desired through supersound process to impel dissolving, shake up, obtaining the solution being all about 150 μ g/mL containing Glycopyrronium Bromide, impurity Iy, impurity Iz three concentration, is standardized solution B;
Standardized solution C: the above standardized solution B that precision measures 1ml is placed in 100ml measuring bottle, adds diluting soln and is diluted to scale, shake up, making the solution being all about 1.5 μ g/mL containing Glycopyrronium Bromide, impurity Iy, impurity Iz three concentration, is standardized solution C;
Standardized solution D: precision takes impurity Iy reference substance and is about 15mg, is placed in 100ml measuring bottle, adds diluting soln and is diluted to scale, if desired through supersound process to impel dissolving, shaking up, obtain the solution that impure Iy concentration is about 150 μ g/mL, is standardized solution Dy; Another precision takes impurity Iz reference substance and is about 15mg, is placed in 100ml measuring bottle, adds diluting soln and is diluted to scale, if desired through supersound process to impel dissolving, shaking up, obtain the solution that impure Iz concentration is about 150 μ g/mL, is standardized solution Dz;
Need testing solution: precision takes the trial-product being about 100mg containing Glycopyrronium Bromide, be placed in 100ml measuring bottle, dissolve with diluting soln and be diluted to scale, if desired through supersound process to impel dissolving, shake up, filter if desired, make and be about the need testing solution of 1000 μ g/mL containing Glycopyrronium Bromide concentration (wherein said trial-product can be the various samples comprising Glycopyrronium Bromide, it can be such as Glycopyrronium Bromide crude product, bulk drug, highly finished product and the preparation be made up of them, need according to concrete mensuration and determine, when measure be preparation time, be converted to the Glycopyrronium Bromide comprised in said preparation appropriate to be mixed with respective concentration---these operative techniquies well known to a person skilled in the art),
(ii) chromatographic system:
Chromatographic run carries out according to Chinese Pharmacopoeia version in 2010 two contained high performance liquid chromatography of annex V D, and chromatographic condition is as follows:
Detector: UV-detector, determined wavelength UV222nm;
Chromatographic column: octadecylsilane chemically bonded silica post, filler granularity 5 μm, column internal diameter 4.6mm, column length 15cm; [note: this is the chromatographic column that a kind of this area is very commonly used]
Gradient elution program:
Time (min) Solution A (%) Solution B (%)
0 100 0
10 100 0
25 10 90
35 10 90
37 100 0
43 100 0
Column temperature: 40 DEG C;
Flow velocity: 1mL/min;
Sample size: 50 μ L;
System suitability: the resolution in standardized solution C color atlas between impurity Iy and Glycopyrronium Bromide is not less than 2.0, the holder tail factor at Glycopyrronium Bromide peak is no more than 2.0, and the relative standard deviation of each chromatographic peak is no more than 6.0%; The retention time of impurity Iy and impurity Iz under this chromatographic condition is determined by the color atlas main peak retention time of standardized solution Dy and standardized solution Dz, and by standardized solution B color atlas determination impurity Iy, impurity Iz, the retention time of Glycopyrronium Bromide and the relative retention time of three;
(iii) measure:
Respectively need testing solution, standardized solution A, standardized solution C injection liquid chromatography are measured, read the peak area of Glycopyrronium Bromide in gained three color atlass, the peak area (when these chromatographic peaks exist) of impurity Iy and impurity Iz and other impurity optionally existed in need testing solution color atlas, the peak area of impurity Iy and impurity Iz in standardized solution C color atlas, and their retention time;
Press external standard method with the concentration of Glycopyrronium Bromide in calculated by peak area need testing solution according to need testing solution color atlas and standardized solution A color atlas, (unit is μ g/mL to be designated as Ci; The calculating formula that well-known external standard method calculates Ci is: Glycopyrronium Bromide concentration in Ci=(in need testing solution color atlas in main peak area ÷ standardized solution A color atlas main peak area) × standardized solution A; The interference such as this despumation of Glycopyrronium Bromide concentration, auxiliary material, moisture, for bulk drug, this concentration may be close with dosing concentration, but the crude product more for impurity and/or moisture etc. and with the addition of auxiliary material pharmaceutical composition such as pharmaceutical preparation for, this concentration can reflect the concentration of Glycopyrronium Bromide in solution exactly);
Be calculated as follows the concentration of impurity Iy or impurity Iz in need testing solution, be designated as respectively Cy or Cz (unit is μ g/mL, when present):
Be calculated as follows the concentration of optional other the single impurity existed in need testing solution, (unit is μ g/mL to be designated as Cn; When there is other impurity multiple, these other impurity calculate separately respectively):
To be calculated as follows in sample impurity Iy or impurity Iz or other single foreign matter content (being percentage composition, %) for Glycopyrronium Bromide:
Impurity Iy content (%)=(Cy ÷ Ci) × 100%,
Impurity Iz content (%)=(Cz ÷ Ci) × 100%,
Other single foreign matter content (%)=(Cn ÷ Ci) × 100%.
Above in [HPLC-B], be 1 or for 1.00 in the relative retention time of Glycopyrronium Bromide, the relative retention time of impurity Iy in 1.10 ~ 1.18 scopes (hereafter in concrete measurement result all within the scope of this, particularly be about 1.14), the relative retention time of impurity Iz in 2.63 ~ 2.73 scopes (hereafter in concrete measurement result all within the scope of this, be particularly about 2.68).
In [HPLC-A] of the present invention or [HPLC-B] testing method, the sample that preparation sample solution is used, it can be the bulk drug of the present invention of contained I and enantiomorph thereof, also can be the pharmaceutical preparation comprising auxiliary material.The latter in this way, then in the material that takes or measure in the amount of contained I and enantiomorph thereof and bulk drug the amount of contained formula I and enantiomorph thereof suitable.
Method according to a first aspect of the present invention, the bulk drug of the present invention comprising Glycopyrronium Bromide obtained by it measures according to the present invention [HPLC-A], wherein relative retention time (also can be described as RRT0.89 impurity at the impurity at 0.86 ~ 0.92 place in the present invention or is called RRT0.89, it is essentially impurity Ix) for Glycopyrronium Bromide content lower than 0.5% (such as lower than 0.4%, such as, lower than 0.3%).
Method according to a first aspect of the present invention, the bulk drug of the present invention comprising Glycopyrronium Bromide obtained by it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT1.14 impurity at the impurity at 1.10 ~ 1.18 places in the present invention or is called RRT1.14, it is essentially impurity Iy) for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope).
Method according to a first aspect of the present invention, the bulk drug of the present invention comprising Glycopyrronium Bromide obtained by it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT2.68 impurity at the impurity at 2.63 ~ 2.73 places in the present invention or is called RRT2.68, it is essentially impurity Iz) for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iz content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 0.500% scope (such as in 0.002% ~ 0.400% scope, such as in 0.002% ~ 0.300% scope, such as in 0.002% ~ 0.250% scope, such as in 0.002% ~ 0.200% scope, such as in 0.002% ~ 0.150% scope, such as in 0.002% ~ 0.130% scope).
The present invention finds, make impurity Iy content control lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope) time, impurity Iz in bulk drug of the present invention and the pharmaceutical composition for preparing thereof can be made not have significant increase along with the prolongation of storage time.The discovery of biological significance is had to be in the present invention, impurity Iz is the material that a kind of toxicity is particularly obviously strong than Glycopyrronium Bromide to the medium lethal dose of Mouse and rat, and impurity Iz has the undesirable action causing Neutrophilic granulocytopenia, particularly as impurity Iz in medical compounds of the present invention and the pharmaceutical composition for preparing thereof relative to the content of formula I lower than 2.0% (such as lower than 1.5%, such as lower than 1.0%, such as lower than 0.75%, such as lower than 0.50%, such as lower than 0.40%) time, this bulk drug or its pharmaceutical composition prepared can not cause obvious Neutrophilic granulocytopenia to animal subject, but when impurity Iz relative content in this bulk drug or its pharmaceutical composition prepared higher than 0.40% (particularly higher than 0.50%, particularly higher than 0.75%, particularly higher than 1.0%, particularly higher than 1.5%, particularly higher than 2.0%) time, this bulk drug or its pharmaceutical composition prepared still can cause this side effect of the obvious Neutrophilic granulocytopenia of animal subject.Therefore, method according to a first aspect of the present invention, comprise in the bulk drug of the present invention of Glycopyrronium Bromide obtained by it, in the pharmaceutical composition be particularly made up of this bulk drug such as pharmaceutical preparation, impurity Iz relative to the content of formula I lower than 2.000% (such as lower than 1.500%, such as, lower than 1.000%, such as, lower than 0.750%, such as lower than 0.500%, such as, lower than 0.400%).
Method according to a first aspect of the present invention, the bulk drug of the present invention comprising Glycopyrronium Bromide obtained by it places 6 months 40 DEG C of condition lower seals, lucifuges, certain impurity phase after 6 months is disposed in calculating with this understanding increases percentage ratio for content when 0 month, wherein measure the foreign matter content of relative retention time at 2.63 ~ 2.73 places according to [HPLC-B] and increase percentage ratio lower than 200%, such as lower than 150%, such as, lower than 100%, such as, lower than 75%, such as lower than 50%, such as, lower than 40%.This test method in the present invention can referred to as investigating 40 DEG C-June.Described term " foreign matter content increase percentage ratio " calculates according to following formula:
In above calculating formula, impurity 0 month content or impurity content in June refer to this impurity relative content relative to Glycopyrronium Bromide in material.
Further, second aspect present invention provides a kind of bulk drug of hyoscine, and the activeconstituents of this bulk drug is Glycopyrronium Bromide.
Or further, second aspect present invention provides a kind of bulk drug of hyoscine, the activeconstituents of this bulk drug is with compounds of Formula I:
(formula I)
And enantiomorph.
That is, in the present invention, Glycopyrronium Bromide refers to the mixture such as racemic mixture with above formula I and enantiomer thereof.
Bulk drug according to a second aspect of the present invention, comprising as the formula I of main ingredient and enantiomorph thereof, and the optional Ix impurity as impurity.
Bulk drug according to a second aspect of the present invention, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.5% (such as lower than 0.4%, such as, lower than 0.3%).
Bulk drug according to a second aspect of the present invention, comprising as the formula I of main ingredient and enantiomorph thereof, and the optional Iy impurity as impurity.
Bulk drug according to a second aspect of the present invention, wherein Iy impurity phase for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope).
Bulk drug according to a second aspect of the present invention, comprising as the formula I of main ingredient and enantiomorph thereof, and the optional Iz impurity as impurity.
Bulk drug according to a second aspect of the present invention, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iz foreign matter content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 0.500% scope (such as in 0.002% ~ 0.400% scope, such as in 0.002% ~ 0.300% scope, such as in 0.002% ~ 0.250% scope, such as in 0.002% ~ 0.200% scope, such as in 0.002% ~ 0.150% scope, such as in 0.002% ~ 0.130% scope).
Bulk drug according to a second aspect of the present invention, it measures according to the present invention [HPLC-A], wherein relative retention time (also can be described as RRT0.89 impurity at the impurity at 0.86 ~ 0.92 place in the present invention or is called RRT0.89, it is essentially impurity Ix) for Glycopyrronium Bromide content lower than 0.5% (such as lower than 0.4%, such as, lower than 0.3%).
Bulk drug according to a second aspect of the present invention, it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT1.14 impurity at the impurity at 1.10 ~ 1.18 places in the present invention or is called RRT1.14, it is essentially impurity Iy) for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iy content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope).
Bulk drug according to a second aspect of the present invention, it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT2.68 impurity at the impurity at 2.63 ~ 2.73 places in the present invention or is called RRT2.68, it is essentially impurity Iz) for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%), such as Iz content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 0.500% scope (such as in 0.002% ~ 0.400% scope, such as in 0.002% ~ 0.300% scope, such as in 0.002% ~ 0.250% scope, such as in 0.002% ~ 0.200% scope, such as in 0.002% ~ 0.150% scope, such as in 0.002% ~ 0.130% scope).
Bulk drug according to a second aspect of the present invention, it places 6 months 40 DEG C of condition lower seals, lucifuges, certain impurity phase after 6 months is disposed in calculating with this understanding increases percentage ratio for content when 0 month, wherein measure the foreign matter content of relative retention time at 2.63 ~ 2.73 places according to [HPLC-B] and increase percentage ratio lower than 200%, such as lower than 150%, such as, lower than 100%, such as, lower than 75%, such as lower than 50%, such as, lower than 40%.
Bulk drug according to a second aspect of the present invention, it obtains to reach refining object by carrying out recrystallization to the bulk drug of contained I and enantiomorph thereof.
Bulk drug according to a second aspect of the present invention, described recrystallization is dissolved in by bulk drug in the first solvent, then in this solution, adds the second solvent, be settled out crystallization to make Glycopyrronium Bromide from solvent.
Bulk drug according to a second aspect of the present invention, wherein said first solvent is selected from: water, methyl alcohol, ethanol, 1-octanol, phenylcarbinol, methyl-sulphoxide, methylene dichloride, ethyl acetate and combination thereof.In one embodiment, described first solvent is selected from: ethanol, 1-octanol, methyl-sulphoxide, methylene dichloride, ethyl acetate and combination thereof.In one embodiment, described first solvent is the mixture of ethanol and ethyl acetate.In one embodiment, described first solvent is the mixture of ethanol and ethyl acetate volume ratio 100:7 ~ 20, preferably the mixture of ethanol and ethyl acetate volume ratio 100:10 ~ 16.In the present invention, if not otherwise indicated, the ethanol mentioned is dehydrated alcohol.
Bulk drug according to a second aspect of the present invention, described second solvent is selected from: ether, methyl ethyl ether, t-butyl methyl ether, normal heptane, normal hexane, Skellysolve A and combination thereof.In one embodiment, described second solvent is selected from: ether, methyl ethyl ether, t-butyl methyl ether and combination thereof.In one embodiment, described second solvent is methyl ethyl ether.
Bulk drug according to a second aspect of the present invention, the volume ratio of wherein said first solvent and the second solvent is 1:7 ~ 25, such as 1:10 ~ 20, such as 1:10 ~ 15.
Further, third aspect present invention provides a kind of pharmaceutical composition (such as pharmaceutical preparation), wherein comprises the bulk drug described in any one of second aspect present invention, and optional pharmaceutically acceptable carrier or auxiliary material.In one embodiment, pharmaceutical composition of the present invention uses the bulk drug described in any one of second aspect present invention to prepare through pharmaceutical composition (such as pharmaceutical preparation) preparation technology.
Pharmaceutical composition according to a third aspect of the present invention, it is oral preparations or injection formulations.
Pharmaceutical composition according to a third aspect of the present invention, it is tablet, capsule, granule, injection (comprising injection liquid and lyophilize powder injection), suspensoid, pill.
Pharmaceutical composition according to a third aspect of the present invention, it is injection liquid.
Pharmaceutical composition according to a third aspect of the present invention, it is injection liquid, comprises in the every 1ml of this injection liquid: the Glycopyrronium Bromide of 0.1 ~ 0.5mg, acid-base modifier and add to the water for injection of full dose.
Pharmaceutical composition according to a third aspect of the present invention, it is injection liquid, comprises in the every 1ml of this injection liquid: the Glycopyrronium Bromide of 0.1 ~ 0.5mg, acid-base modifier are in right amount to regulate the pH value of injection liquid in 2.0 ~ 3.0 scopes and to add to the water for injection of full dose.In one embodiment, described acid-base modifier is hydrochloric acid and/or sodium hydroxide, can also be well known to a person skilled in the art other acid-base modifier.
Pharmaceutical composition according to a third aspect of the present invention, it is injection liquid, comprises the Glycopyrronium Bromide of 0.15 ~ 0.25mg in the every 1ml of this injection liquid.In one embodiment, the Glycopyrronium Bromide of 0.2mg is comprised in the every 1ml of this injection liquid.
Pharmaceutical composition according to a third aspect of the present invention, it is injection liquid, wherein also optionally comprises phenylcarbinol.In one embodiment, the Benzyl alcohol concentrations in this injection liquid is 0.5 ~ 1.5mg/ml, and such as Benzyl alcohol concentrations is 0.7 ~ 1.2mg/ml, and such as Benzyl alcohol concentrations is 0.8 ~ 1.0mg/ml, and such as Benzyl alcohol concentrations is 0.9mg/ml.
Pharmaceutical composition according to a third aspect of the present invention, it is lyophilize powder injection, comprises in this powder injection: the Glycopyrronium Bromide of 0.2 weight part, the freeze-dried excipient of 20 ~ 400 weight parts.
Pharmaceutical composition according to a third aspect of the present invention, it is lyophilize powder injection, comprises in this powder injection: the Glycopyrronium Bromide of 0.2 weight part, the freeze-dried excipient of 20 ~ 400 weight parts, optional pH adjusting agent in right amount with make this powder injection water for injection be diluted to pH value that Glycopyrronium Bromide concentration is solution during 0.2mg/ml in 2.0 ~ 3.0 scopes.
Pharmaceutical composition according to a third aspect of the present invention, it is lyophilize powder injection, comprises in this powder injection: the Glycopyrronium Bromide of 0.2 weight part, the freeze-dried excipient of 50 ~ 250 weight parts, optional pH adjusting agent in right amount with make this powder injection water for injection be diluted to pH value that Glycopyrronium Bromide concentration is solution during 0.2mg/ml in 2.0 ~ 3.0 scopes.
In one embodiment, described freeze-dried excipient can be selected from N.F,USP MANNITOL, lactose, maltose, sucrose, sodium-chlor etc.
Pharmaceutical composition according to a third aspect of the present invention, comprising the Glycopyrronium Bromide as active ingredient, and the optional Ix impurity as impurity.
Pharmaceutical composition according to a third aspect of the present invention, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 1.0% (such as lower than 0.75%, such as, lower than 0.5%, such as, lower than 0.4%).
Pharmaceutical composition according to a third aspect of the present invention, comprising the Glycopyrronium Bromide as active ingredient, and the optional Iy impurity as impurity.
Pharmaceutical composition according to a third aspect of the present invention, wherein Iy impurity phase for Glycopyrronium Bromide content lower than 0.75% (such as lower than 0.50%, lower than 0.4%, lower than 0.3%), such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.750% scope (such as in 0.003% ~ 0.500% scope, such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope).
Pharmaceutical composition according to a third aspect of the present invention, comprising the Glycopyrronium Bromide as active ingredient, and the optional Iz impurity as impurity.
Pharmaceutical composition according to a third aspect of the present invention, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 1.00% (such as lower than 0.75%, lower than 0.50%, lower than 0.4%), such as Iz foreign matter content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 1.000% scope (such as in 0.002% ~ 0.750% scope, such as in 0.002% ~ 0.500% scope, such as in 0.002% ~ 0.400% scope).
Pharmaceutical composition according to a third aspect of the present invention, it measures according to the present invention [HPLC-A], wherein relative retention time (also can be described as RRT0.89 impurity at the impurity at 0.86 ~ 0.92 place in the present invention or is called RRT0.89, it is essentially impurity Ix) for Glycopyrronium Bromide content lower than 1.0% (such as lower than 0.75%, such as lower than 0.5%, such as, lower than 0.4%).
Pharmaceutical composition according to a third aspect of the present invention, it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT1.14 impurity at the impurity at 1.10 ~ 1.18 places in the present invention or is called RRT1.14, it is essentially impurity Iy) for Glycopyrronium Bromide content lower than 0.75% (such as lower than 0.50%, lower than 0.4%, lower than 0.3%), such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.750% scope (such as in 0.003% ~ 0.500% scope, such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope).
Pharmaceutical composition according to a third aspect of the present invention, it measures according to the present invention [HPLC-B], wherein relative retention time (also can be described as RRT2.68 impurity at the impurity at 2.63 ~ 2.73 places in the present invention or is called RRT2.68, it is essentially impurity Iz) for Glycopyrronium Bromide content lower than 1.00% (such as lower than 0.75%, lower than 0.50%, lower than 0.4%), such as Iz foreign matter content (relative to Glycopyrronium Bromide meter) in 0.002% ~ 1.000% scope (such as in 0.002% ~ 0.750% scope, such as in 0.002% ~ 0.500% scope, such as in 0.002% ~ 0.400% scope).
Pharmaceutical composition according to a third aspect of the present invention, it places 4 months 40 DEG C of condition lower seals, lucifuges, certain impurity phase after 4 months is disposed in calculating with this understanding increases percentage ratio for content when 0 month, wherein the foreign matter content of relative retention time at 2.63 ~ 2.73 places increases percentage ratio lower than 200%, such as lower than 150%, such as, lower than 100%, such as, lower than 75%, such as lower than 50%, such as, lower than 40%.This test method in the present invention can referred to as investigating 40 DEG C-April.
Further, fourth aspect present invention provides the purposes of pharmaceutical composition described in bulk drug described in bulk drug that method described in first aspect present invention prepares, second aspect or the third aspect, for the preparation of narcotic or for the preparation for the treatment of and or the medicine of prevention peptide ulceration.
According to either side of the present invention, in wherein said Medicinal crude drug, the content of Glycopyrronium Bromide is greater than 99.0%, such as, be greater than 99.5%.This content can measure according to the method under version Chinese Pharmacopoeia in 2010 two 814 pages Glycopyrronium Bromide [assay] items.
According to either side of the present invention, the chromatographic purity that wherein said Medicinal crude drug measures according to the present invention [HPLC-A] in 98.00% ~ 99.99% scope, such as, in 98.50% ~ 99.99% scope, such as, in 99.00% ~ 99.99% scope.Term " chromatographic purity " is the result of trial-product color atlas being carried out to area normalization method calculating, and deduction solvent, auxiliary material isochromatic spectrum peak and the result that obtains, it is different from content mentioned above.
According to either side of the present invention, the chromatographic purity that wherein said Medicinal crude drug measures according to the present invention [HPLC-B] in 98.00% ~ 99.99% scope, such as, in 98.50% ~ 99.99% scope, such as, in 99.00% ~ 99.99% scope.
Arbitrary embodiment of either side of the present invention, can combine, as long as they there will not be contradiction with other arbitrary embodiment of either side.In addition, in arbitrary embodiment of either side of the present invention, arbitrary technical characteristic goes for this technical characteristic in other embodiment, as long as they there will not be contradiction.
In the present invention, the implication of " % " can be determined according to concrete environment for use, and particularly it has as implication as described in Article 28 (4) money under " metering " item in version Chinese Pharmacopoeia in 2010 two notes on the use.
In the present invention, when mentioning separately, " ethanol " refers to dehydrated alcohol.
In the present invention, each carbon atom of Glycopyrronium Bromide can number indicate as follows:
namely Glycopyrronium Bromide represents 3R2S Glycopyrronium Bromide and 3S2R Glycopyrronium Bromide.
Also the numbering indicating each carbon atom in document such as CN102627595A is in the following manner had:
namely Glycopyrronium Bromide represents 3R2 ' S Glycopyrronium Bromide and 3S2 ' R Glycopyrronium Bromide.
In addition, all right called after of Glycopyrronium Bromide: bromination (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxyl-2-phenyl acetyl) oxygen base]-1,1-dimethyl pyrrolidine.
In the present invention, although the present inventor has known the particular chemical of RRT0.89, RRT1.14, RRT2.68 tri-specific impurities, but these impurity also carry out qualitative characterization by it in [HPLC-A] and [HPLC-B] of specific, concrete of the present invention, and the RRT parameter presented under being especially for use in specific HPLC condition characterizes.As well known to those skilled in the art, RRT can be completely independently used to characterize and its particular chemical need not be considered completely, reason is that RRT is the parameter of a substantially constant under regulation HPLC condition, and namely RRT characterizes and can use separate or in combination with one another with structural characterization.And this characterizing method is pharmaceutical field allowed bulk drug or preparation quality standard, possesses industrial applicability completely.
In the present invention, if not otherwise indicated, when determining the content of Glycopyrronium Bromide or other impurity in various material (such as various as pharmaceutical preparation bulk drug, pharmaceutical composition such as pharmaceutical preparation etc.), and when determining in these materials chromatographic purity, can all adopt the method for [HPLC-A] mentioned above and [HPLC-B] to measure.
" pharmaceutically acceptable carrier " that use in pharmaceutical composition of the present invention can be the carrier of any routine in field of pharmaceutical preparations.The selection of specific support will depend on the administering mode or disease type and state that are used for the treatment of particular patient.For the preparation method of the said synthetic processes of specific administration pattern completely in the ken of pharmaceutical field technician.Such as, the thinner of pharmaceutical field routine, carrier, weighting agent, tackiness agent, wetting agent, disintegrating agent, absorption enhancer, tensio-active agent, absorption carrier and lubricant etc. can be comprised as pharmaceutically acceptable carrier.If desired, flavouring agent, preservative and sweetener etc. can also be added in pharmaceutical composition.
Pharmaceutical composition of the present invention can make the various ways such as tablet, pulvis, granule, capsule, oral liquid, paste, creme, injectable emulsion (aseptic powder needle for injection).The medicine of above-mentioned various formulation all can be prepared according to the ordinary method of pharmaceutical field.
Neutrophil leucocyte (Neutrophil or Neutrophilgranulocyte can be abbreviated as NG in the present invention) is the one of blood leucocyte, is also topmost a kind of white corpuscle in mammalian.Neutrophil leucocyte plays a very important role in the Nonspecific immunity system of blood, it is in body and resists microbial pathogen, particularly at the First Line of suppurative bacterium invasion, when inflammation occurs, they are attracted to inflammation part by chemotaxis material.Because they borrow glycolysis-to obtain energy, therefore still can survive under the anaerobic conditions of thrombosis in swelling, they form cell toxicant here and there is the cytolemma destroying bacterium and neighbouring tissue.Owing to containing a large amount of lysosomal enzyme in neutrophil leucocyte, therefore can engulf and decompose into intracellular bacterium and fragment of tissue, like this, the bacterium of invasion is enclosed in a local, and eliminates, and prevents pathogenic micro-organism from spreading in vivo.When neutrophil leucocyte itself disintegrates, disengaging each lysosomal enzymes can dissolve surrounding tissue and form abscess.The cytolemma of neutrophil leucocyte can discharge a kind of unsaturated fatty acids---arachidonic acid, under the effect of enzyme, one group of paracrine hormone substance is generated again further by it, as thromboxane and prostaglandin(PG) etc., this kind of material has obvious effect to adjustment external caliber and permeability, can also be caused inflammation reaction and pain, and affect blood coagulation.Thus, in blood of human body, Neutrophilic granulocytopenia is disadvantageous for the performance of the normal physiological function of human body.
The Glycopyrronium Bromide medicament (such as tablet, oral liquid, injection liquid etc.) of now list marketing, its as a kind of anticholinergic drug can be used for treat peptide ulceration and for performing the operation time anesthesia etc.The invention provides a kind of new Glycopyrronium Bromide bulk drug, it has excellent feature in stability, and demonstrate good biological safety, therefore material medicine of the present invention can be used for treatment peptide ulceration equally and has a low rate of side effects for surgery anesthesia.
Embodiment
Can be conducted further description the present invention by the following examples, but scope of the present invention is not limited to following embodiment.One of skill in the art can understand, and under the prerequisite not deviating from the spirit and scope of the present invention, can carry out various change and modification to the present invention.The present invention carries out generality and/or concrete description to the material used in test and test method.Although for realizing many materials that the object of the invention uses and working method is well known in the art, the present invention still describes in detail as far as possible at this.
Use [HPLC-A] method to measure when measuring the RRT0.89 content of each material below, measure RRT1.14 content and RRT2.68 content then uses [HPLC-B] method to measure.
embodiment 1: prepare Glycopyrronium Bromide bulk drug
Step (1), synthetic compound of formula i and enantiomorph thereof:
Hydroxycyclopent base methyl mandelate (MCPM) and N-methylpyrrolidin-3-alcohol (NMP) is made to be obtained by reacting the grand amine alkali of lattice (GP alkali) according to the method in US2956062A, then according to CN101133021B specification sheets [0015]-[0017] section institute support method, the grand amine alkali of lattice and monobromethane are reacted then to carry out recrystallizing and refining to products therefrom, obtain Glycopyrronium Bromide.
RRT0.89 content=4.63%, RRT1.14 content=1.78%, RRT2.68 content=1.14%.
Step (2), recrystallizing and refining:
At the temperature of 55 ~ 60 DEG C, step (1) products therefrom 1.5g is dissolved in dehydrated alcohol-ethyl acetate mixed solvent (100:12, v/v) in 10ml, slowly drip methyl ethyl ether 120ml wherein, leave standstill at 4 ~ 5 ° and make abundant precipitation (about 24 hours), leach precipitation, wash with methyl ethyl ether, vacuum-drying, obtains (recrystallization yield 90.2%).
RRT0.89 content=0.77%, RRT1.14 content=0.39%, RRT2.68 content=0.23%.After measured, its MSm/z:318 (M-Br -), 1the contained Glycopyrronium Bromide of HNMR and CN103159659A specification sheets final stage is identical.
This time recrystallization purifying, RRT0.89 content reduces 83%[i.e. (4.63-0.77) ÷ 4.63 × 100%, and it is applicable equally hereinafter that this content reduces percentage ratio method of calculation], RRT1.14 content reduces by 78%, RRT2.68 content and reduces by 80%.
Step (3), again recrystallizing and refining:
At the temperature of 55 ~ 60 DEG C, step (2) products therefrom 1.0g is dissolved in dehydrated alcohol-ethyl acetate mixed solvent (100:10, v/v) in 10ml, slowly drip methyl ethyl ether 100ml wherein, leave standstill at 8 ~ 10 ° and make abundant precipitation (about 36 hours), leach precipitation, wash with methyl ethyl ether, vacuum-drying, obtains (recrystallization yield 94.1%).
RRT0.89 content=0.12%, RRT1.14 content=0.08%, RRT2.68 content=0.05%.This time recrystallization purifying, RRT0.89 content reduces by 84%, RRT1.14 content and reduces by 79%, RRT2.68 content reduction by 78%.
Step (4), again recrystallizing and refining:
At the temperature of 55 ~ 60 DEG C, step (3) products therefrom 0.5g is dissolved in dehydrated alcohol-ethyl acetate mixed solvent (100:16, v/v) in 2.5ml, slowly drip methyl ethyl ether 37.5ml wherein, leave standstill at 0 ~ 2 ° and make abundant precipitation (about 18 hours), leach precipitation, wash with methyl ethyl ether, vacuum-drying, obtains (recrystallization yield 91.6%).
RRT0.89 content=0.021%, RRT1.14 content=0.018%, RRT2.68 content=0.011%.This time recrystallization purifying, RRT0.89 content reduces by 83%, RRT1.14 content and reduces by 78%, RRT2.68 content reduction by 78%.
Step (5), again recrystallizing and refining:
By step (4) products therefrom according to step (4) method recrystallizing and refining again, make to measure weight loss on drying after vacuum-drying at 105 DEG C and be less than 0.1%, method under Chinese Pharmacopoeia version in 2010 two 814 pages Glycopyrronium Bromide [assay] items measures, dry product Glycopyrronium Bromide (C19H28BrNO3) content is 99.97%, RRT0.89 content=0.004%, RRT1.14=0.003%, RRT2.68=0.002%.
To when each batch of sample is tested above, in [HPLC-A] method, the relative retention time of RRT0.89 impurity is all in 0.88 ~ 0.91 scope, and Glycopyrronium Bromide retention time is all about 11.3 ~ 11.7min; In [HPLC-B] method, the relative retention time of RRT1.14 impurity is all in 1.12 ~ 1.16 scopes, and the relative retention time of RRT2.68 impurity is all in 2.65 ~ 2.71 scopes, and Glycopyrronium Bromide retention time is all about 8.2 ~ 8.6min.
Step (2) all can be used as Glycopyrronium Bromide bulk drug of the present invention to step (5) products therefrom, particularly step (3) to step (5) products therefrom above, such as, use for the preparation of pharmaceutical preparation.Step (5) products therefrom also can be used as Glycopyrronium Bromide reference substance in addition, uses as test.
embodiment 2: prepare Glycopyrronium Bromide bulk drug
Step (1), synthetic compound of formula i and enantiomorph thereof:
Glycopyrronium Bromide crude product is prepared to [0013] section 4 row institute support method according to the method for CN103159659A specification sheets embodiment part and specification sheets [0010] section.RRT0.89 content=4.76%, RRT1.14 content=1.61%, RRT2.68 content=1.21%.
Step (2), recrystallizing and refining:
Get above step (1) products therefrom and carry out recrystallization (recrystallization yield 89.7%) according to the embodiment of the present invention 1 step (2) method.
RRT0.89 content=0.83%, RRT1.14 content=0.34%, RRT2.68 content=0.20%.This time recrystallization purifying, RRT0.89 content reduces by 82%, RRT1.14 content and reduces by 79%, RRT2.68 content reduction by 83%.
Step (3), again recrystallizing and refining:
Get above step (2) products therefrom and carry out recrystallization (recrystallization yield 93.5%) according to the embodiment of the present invention 1 step (3) method.
RRT0.89 content=0.17%, RRT1.14 content=0.06%, RRT2.68 content=0.04%.This time recrystallization purifying, RRT0.89 content reduces by 80%, RRT1.14 content and reduces by 82%, RRT2.68 content reduction by 80%.
Step (4), again recrystallizing and refining:
Get above step (3) products therefrom and carry out recrystallization (recrystallization yield 91.2%) according to the embodiment of the present invention 1 step (4) method.
RRT0.89 content=0.023%, RRT1.14 content=0.010%, RRT2.68 content=0.007%.This time recrystallization purifying, RRT0.89 content reduces by 86%, RRT1.14 content and reduces by 83%, RRT2.68 content reduction by 82%.After measured, its MSm/z:318 (M-Br -), 1the contained Glycopyrronium Bromide of HNMR and CN103159659A specification sheets final stage is identical.
To when each batch of sample is tested above, in [HPLC-A] method, the relative retention time of RRT0.89 impurity is all in 0.86 ~ 0.92 scope, in [HPLC-B] method, the relative retention time of RRT1.14 impurity is all in 1.10 ~ 1.18 scopes, and the relative retention time of RRT2.68 impurity is all in 2.63 ~ 2.73 scopes.
Above step (2) all can be used as Glycopyrronium Bromide bulk drug of the present invention to step (4) products therefrom, particularly step (3) to step (4) products therefrom, such as, use for the preparation of pharmaceutical preparation.
embodiment 3: prepare Glycopyrronium Bromide bulk drug
Step (1), synthetic compound of formula i and enantiomorph thereof:
Glycopyrronium Bromide is prepared to [0046] section institute support method according to the method for CN102627595A specification sheets embodiment part and specification sheets [0043] section.RRT0.89 content=4.13%, RRT1.14 content=1.36%, RRT2.68 content=1.03%.
Step (2), recrystallizing and refining:
Get above step (1) products therefrom and carry out recrystallization (recrystallization yield 92.4%) according to the embodiment of the present invention 1 step (2) method.
RRT0.89 content=0.70%, RRT1.14 content=0.24%, RRT2.68 content=0.16%.This time recrystallization purifying, RRT0.89 content reduces by 83%, RRT1.14 content and reduces by 82%, RRT2.68 content reduction by 84%.
Step (3), again recrystallizing and refining:
Get above step (2) products therefrom and carry out recrystallization (recrystallization yield 92.0%) according to the embodiment of the present invention 1 step (3) method.
RRT0.89 content=0.12%, RRT1.14 content=0.048%, RRT2.68 content=0.027%.This time recrystallization purifying, RRT0.89 content reduces by 83%, RRT1.14 content and reduces by 80%, RRT2.68 content reduction by 83%.
Step (4), again recrystallizing and refining:
Get above step (3) products therefrom and carry out recrystallization (recrystallization yield 93.1%) according to the embodiment of the present invention 1 step (4) method.
RRT0.89 content=0.021%, RRT1.14 content=0.009%, RRT2.68 content=0.005%.This time recrystallization purifying, RRT0.89 content reduces by 85%, RRT1.14 content and reduces by 81%, RRT2.68 content reduction by 81%.After measured, its MSm/z:318 (M-Br -), 1the contained Glycopyrronium Bromide of HNMR and CN103159659A specification sheets final stage is identical.
To when each batch of sample is tested above, in [HPLC-A] method, the relative retention time of RRT0.89 impurity is all in 0.86 ~ 0.92 scope, in [HPLC-B] method, the relative retention time of RRT1.14 impurity is all in 1.10 ~ 1.18 scopes, and the relative retention time of RRT2.68 impurity is all in 2.63 ~ 2.73 scopes.
Above step (2) all can be used as Glycopyrronium Bromide bulk drug of the present invention to step (4) products therefrom, particularly step (3) to step (4) products therefrom, such as, use for the preparation of pharmaceutical preparation.
comparing embodiment 1: with reference to the operation of this paper embodiment 1 step (3), different is only by wherein the first solvent and dehydrated alcohol-ethyl acetate mixed solvent replaces with ethanol and water, methyl alcohol, 1-octanol, phenylcarbinol, ethyl acetate with the mixed solution of volume ratio (100:10), obtained 5 batches of products.Calculate these 5 batches of products RRT0.89, RRT1.14, RRT2.68 three content after this recrystallization purifying and reduce degree, the content of result RRT0.89 reduces all in 31.3 ~ 57.4% scopes, the content of RRT1.14 reduces all in 27.8 ~ 55.6% scopes, the content of RRT2.68 reduces all in 33.6 ~ 53.8% scopes, low more than content reduction at least 75% when using dehydrated alcohol of the present invention-ethyl acetate mixed solvent.
comparing embodiment 2: with reference to the operation of this paper embodiment 1 step (3), different is only by wherein the first solvent and dehydrated alcohol-ethyl acetate mixed solvent 100:10 volume ratio change 100:0,100:5,100:20 or 100:30 into, obtained 4 batches of products.Calculate these 4 batches of products and reduce degree through this recrystallization purifying rear impurity content, the content of result RRT0.89 reduces all in 24.1 ~ 52.3% scopes, the content of RRT1.14 reduces all in 17.4 ~ 58.6% scopes, and the content of RRT2.68 reduces all in 21.3 ~ 42.3% scopes.
comparing embodiment 3: with reference to the operation of this paper embodiment 1 step (3), different is only by wherein the second solvent and normal hexane replace with ether, t-butyl methyl ether, normal heptane, normal hexane, obtained 4 batches of products.Calculate these 4 batches of products and reduce degree through this recrystallization purifying rear impurity content, the content of result RRT0.89 reduces and all reduces all lower than 38% lower than the content of 41%, RRT2.68 lower than the content reduction of 48%, RRT1.14.
comparing embodiment 4: get the product of the embodiment of the present invention 1 step (2) and the product of embodiment 2 step (2), the method respectively according to CN101133021B specification sheets [0021] section carries out recrystallization, obtained 2 batches of products.Calculate these 2 batches of products and reduce degree through this recrystallization purifying rear impurity content, the content of result RRT0.89 reduces and all reduces all lower than 55% lower than the content of 41%, RRT2.68 lower than the content reduction of 52%, RRT1.14.
comparing embodiment 5: prepare a collection of Glycopyrronium Bromide product (can #021B be designated as in the present invention) according to CN101133021B specification sheets [0014] to [0021] section institute support method.
#021B measures according to the present invention [HPLC-A] and [HPLC-B], RRT0.89 content=0.312%, RRT1.14 content=0.193%, RRT2.68 content=0.176%.
The contained HPLC method of CN101133021B specification sheets [0022] to [0034] section is adopted to detect #021B and foregoing embodiments of the present invention 3 step (3) and step (4) products therefrom three, result is for the impurity at RRT0.95 place, be 0.14% in #021B sample, being 0.06% in embodiment 3 step (3) sample, is 0.011% in embodiment 3 step (4) sample.Even if suppose that this RRT0.95 and RRT0.89 of the present invention is same substance, then show that the HPLC method sensitivity of CN101133021B is low, may test leakage be had.
preparation example 1: preparation RRT0.89 impurity (impurity Ix)
3S is prepared respectively according to CN103012231A specification sheets [0049] to [0052] phase method, 2 ' S-Glycopyrronium Bromide and 3R, 2 ' R-Glycopyrronium Bromide, respectively through recrystallized from acetonitrile make they in the present invention [HPLC-A] method chromatographic purity all more than 98.5%, the two in this chromatography relative to the relative retention time of 3R2S/3S2R Glycopyrronium Bromide of the present invention all in 0.88 ~ 0.91 scope.By both this with the mixing of 1:1 weight ratio, obtain RRT0.89 impurity, i.e. the erythro isomer (impurity Ix) of Glycopyrronium Bromide of the present invention, can be used as chemical test of the present invention or biological test uses.
preparation example 2: preparation RRT1.14 impurity (i.e. GP alkali, impurity Iy)
The grand amine alkali of lattice is prepared according to the method described in US2956062A, chromatographic purity is purified in the present invention [HPLC-B] method more than 98.5% through acetone recrystallization, its in this chromatography relative to the relative retention time of 3R2S/3S2R Glycopyrronium Bromide of the present invention in 1.13 ~ 1.15 scopes, obtaining RRT1.14 impurity (impurity Iy), can be that chemical test or biological test use do the present invention.
test example 1: the performance test of bulk drug of the present invention
The physicochemical data of the Glycopyrronium Bromide material of testing example 1 step (2) ~ step (5), embodiment 2 step (2) ~ step (4), embodiment 3 step (2) ~ step (4), each batch of comparing embodiment 1 ~ 4 gained, result is as follows:
(1) appearance character: be white crystalline powder.
(2) fusing point: all within the scope of 192 ~ 196 DEG C, molten apart from being all no more than 2 DEG C.
(3) measure according to Chinese Pharmacopoeia version in 2010 two 814 pages every detection methods of contained Glycopyrronium Bromide, the Glycopyrronium Bromide sample of these batches of result all meets this standard regulation.
test example 2: the study on the stability of bulk drug
Get above embodiment 1 step (1) ~ step (5), embodiment 2 step (1) ~ step (4), the Glycopyrronium Bromide material of embodiment 3 step (1) ~ each batch of step (4) gained, #021B sample, and by embodiment 1 step (5) gained Glycopyrronium Bromide and preparation example 1 gained impurity Ix, preparation example 2 gained impurity Iy, and/or commercially available gained impurity Iz mixes (with a little anhydrous alcohol solution with certain proportion, vacuum-drying immediately fully mixes to make them, measure wherein Ix, Iy and/or Iz is relative to the content of Glycopyrronium Bromide) make assembly thing.
These materials are sealed, places 6 months 40 DEG C of condition lower seals, lucifuges, calculate and dispose certain impurity phase after 6 months with this understanding percentage ratio is increased for the content of this impurity 0 month time.
Found that, in various content situation, impurity Ix and impurity Iy increased percentage ratio all lower than 36% relative to its content 0 month time 6 months time.Such as, impurity Ix in embodiment 1 step (1) sample, being 4.63% 0 month time, is 5.97% when June, and it is 29% [algorithm: (5.97%-4.63%)/4.63% × 100%=29%, lower same] that impurity Ix content increases percentage ratio.Impurity Iy again in such as embodiment 1 step (2) sample, being 0.39% 0 month time, is 0.51% when June, and it is 31% that impurity Iy content increases percentage ratio.
But for impurity Iz, it increases percentage ratio at the content of high-temperature treatment after 6 months and but shows relevant with impurity Iy content in sample: when impurity Iy content lower than 0.130% time, impurity Iz content increases percentage ratio all lower than 33%; But when impurity Iy content is greater than 0.150%, impurity Iz content increases percentage ratio display and is increased to more than 90%, and in sample, impurity Iy content higher then impurity Iz content increase percentage ratio is larger.Such as, impurity Iy=0.39% in embodiment 1 step (2) sample, this sample June rear impurity Iz be increased to 0.75% by original 0.23%, impurity Iz content increase percentage ratio reach 226%; And the impurity Iy=0.08% in embodiment 1 step (3) sample, this sample June rear impurity Iz be increased to 0.062% by original 0.05%, impurity Iz content increase percentage ratio be only 24%.It is 129% that #021B increases percentage ratio at the content of high-temperature treatment 6 months rear impurity Iz.Concrete outcome is in table 1.
Table 1:
No. Sample (source or assembly thing) Feature (0 month Ix, Iy, Iz% content) June, Iz increased percentage ratio
1 Ex1S(1) Ix=4.63，Iy=1.78，Iz=1.14 >500%
2 Ex1S(2) Ix=0.77，Iy=0.39，Iz=0.23 226%
3 Ex1S(3) Ix=0.12，Iy=0.08，Iz=0.05 24%
4 Ex1S(4) Ix=0.021、Iy=0.018、Iz=0.011 21%
5 Ex2S(1) Ix=4.76、Iy=1.61、Iz=1.21 >500%
6 Ex2S(2) Ix=0.83、Iy=0.34、Iz=0.20 213%
7 Ex2S(3) Ix=0.17、Iy=0.06、Iz=0.04 26%
8 Ex2S(4) Ix=0.023、Iy=0.010、Iz=0.007 19%
9 Ex3S(1) Ix=4.13、Iy=1.36、Iz=1.03 >400%
10 Ex3S(2) Ix=0.70、Iy=0.24、Iz=0.16 151%
11 Ex3S(3) Ix=0.12、Iy=0.048、Iz=0.027 19%
12 Ex3S(4) Ix=0.021、Iy=0.009、Iz=0.005 24%
More than in table, secondary series Ex1S (1) represents the embodiment of the present invention 1 step (1) products therefrom, this product is as sample, wherein each impurity phase is listed in the 3rd row " feature (Ix, Iy, Iz% content) " for the content of Glycopyrronium Bromide, and other statement all has similar meaning.
Table 2:
No. Sample (source or assembly thing) Feature (0 month Ix, Iy, Iz% content) June, Iz increased percentage ratio
1 Ex1S(5) Ix=0.004，Iy=0.003、Iz=0.002 17%
2 Ex1S(5)+Iy Ix=0.004，Iy=0.010、Iz=0.002 13%
3 Ex1S(5)+Iy Ix=0.004，Iy=0.025、Iz=0.002 23%
4 Ex1S(5)+Iy Ix=0.004，Iy=0.050、Iz=0.002 26%
5 Ex1S(5)+Iy Ix=0.004，Iy=0.075、Iz=0.002 19%
6 Ex1S(5)+Iy Ix=0.004，Iy=0.100、Iz=0.002 32%
7 Ex1S(5)+Iy Ix=0.004，Iy=0.130、Iz=0.002 29%
8 Ex1S(5)+Iy Ix=0.004，Iy=0.150、Iz=0.002 93%
9 Ex1S(5)+Iy Ix=0.004，Iy=0.175、Iz=0.002 115%
10 Ex1S(5)+Iy Ix=0.004，Iy=0.200、Iz=0.002 117%
11 Ex1S(5)+Iy Ix=0.004，Iy=0.250、Iz=0.002 156%
12 Ex1S(5)+Iy Ix=0.004，Iy=0.300、Iz=0.002 194%
13 Ex1S(5)+Iy Ix=0.004，Iy=0.500、Iz=0.002 258%
14 Ex1S(5)+Iy Ix=0.004，Iy=0.750、Iz=0.002 >300%
15 Ex1S(5)+Iy Ix=0.004，Iy=1.000、Iz=0.002 >400%
16 Ex1S(5)+Iy Ix=0.004，Iy=1.500、Iz=0.002 >500%
17 Ex1S(5)+Iy Ix=0.004，Iy=2.000、Iz=0.002 >500%
More than in table, secondary series Ex1S (5)+Iy represents that the embodiment of the present invention 1 step (5) products therefrom and preparation example 2 gained impurity Iy carry out assembly, in assembly thing, each impurity phase is listed in the 3rd row " feature (Ix, Iy, Iz% content) " for the content of Glycopyrronium Bromide, and other statement all has similar meaning.
Table 3:
No. Sample (source or assembly thing) Feature (0 month Ix, Iy, Iz% content) June, Iz increased percentage ratio
1 Ex1S(4)+Iy Ix=0.021、Iy=0.030、Iz=0.011 25%
2 Ex1S(4)+Iy Ix=0.021、Iy=0.050、Iz=0.011 18%
3 Ex1S(4)+Iy Ix=0.021、Iy=0.075、Iz=0.011 25%
4 Ex1S(4)+Iy Ix=0.021、Iy=0.100、Iz=0.011 32%
5 Ex1S(4)+Iy Ix=0.021、Iy=0.130、Iz=0.011 30%
6 Ex1S(4)+Iy Ix=0.021、Iy=0.150、Iz=0.011 97%
7 Ex1S(4)+Iy Ix=0.021、Iy=0.200、Iz=0.011 121%
8 Ex1S(4)+Iy Ix=0.021、Iy=0.300、Iz=0.011 181%
9 Ex1S(4)+Iy Ix=0.021、Iy=0.500、Iz=0.011 266%
10 Ex1S(4)+Iy Ix=0.021、Iy=0.750、Iz=0.011 >300%
11 Ex1S(4)+Iy Ix=0.021、Iy=1.000、Iz=0.011 >400%
Table 4:
No. Sample (source or assembly thing) Feature (0 month Ix, Iy, Iz% content) June, Iz increased percentage ratio
1 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.030、Iz=0.200 27%
2 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.050、Iz=0.200 21%
3 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.075、Iz=0.200 24%
4 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.100、Iz=0.200 28%
5 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.130、Iz=0.200 31%
6 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.150、Iz=0.200 103%
7 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.200、Iz=0.200 132%
8 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.300、Iz=0.200 197%
9 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.500、Iz=0.200 271%
10 Ex2S(4)+Iy+Iz Ix=0.023、Iy=0.750、Iz=0.200 >300%
11 Ex2S(4)+Iy+Iz Ix=0.023、Iy=1.000、Iz=0.200 >400%
More than in table, secondary series Ex2S (4)+Iy+Iz represents that the embodiment of the present invention 2 step (4) products therefrom and preparation example 2 gained impurity Iy and commercially available impurity Iz carry out assembly, in assembly thing, each impurity phase is listed in the 3rd row " feature (Ix, Iy, Iz% content) " for the content of Glycopyrronium Bromide, and other statement all has similar meaning.In table, result is visible, and the impurity Iz increased even if appropriate in sample body measures to 0.200%, and it is still relevant with the impurity Iy in sample that its content increases trend.
In addition, with reference to the assembly thing of above table 4, for the amount of Glycopyrronium Bromide, reach 0.5% unlike adding certain amount of impurity Ix in each sample more in the composition to it.Obtain 11 assembly things and carry out 40 DEG C of disposal in 6 months equally, result impurity Ix and impurity Iy increased percentage ratio all lower than 33% relative to its content 0 month time 6 months time.Such as, but impurity Iz increased the assembly thing result substantially identical (being all no more than 5 percentage points) of percentage ratio and impurity Iy content corresponding in table 46 months time relative to its content 0 month time, it is 136% that the Iz of corresponding to the sample of table 4 numbering 7 assembly thing increases percentage ratio.
After tested, the sample that wherein impurity Ix content is minimum is 0.004% to the Glycopyrronium Bromide that can be used as bulk drug that these are prepared above, and the sample that impurity Iy content is minimum is 0.003%, and the sample that impurity Iz content is minimum is 0.002%.Obviously, with regard to bulk drug of the present invention, wherein impurity Iy for Glycopyrronium Bromide content lower than 0.50% (such as lower than 0.30%, lower than 0.25%, lower than 0.20%, lower than 0.15%, lower than 0.13%) be useful, such as Iy content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.500% scope (such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope, such as in 0.003% ~ 0.250% scope, such as in 0.003% ~ 0.200% scope, such as in 0.003% ~ 0.150% scope, such as in 0.003% ~ 0.130% scope) be useful.After tested the above-mentioned Glycopyrronium Bromide that can be used as bulk drug for their impurity Iy for Glycopyrronium Bromide content lower than 0.13% sample, their impurity Ix for Glycopyrronium Bromide content all lower than 0.3%, their impurity Iz for Glycopyrronium Bromide content all lower than 0.13%.---namely for can be used as Glycopyrronium Bromide bulk drug of the present invention, as one embodiment of the invention, in Glycopyrronium Bromide bulk drug of the present invention, impurity Ix for Glycopyrronium Bromide content lower than 0.3% (being such as 0.004% ~ 0.300%), impurity Iy for Glycopyrronium Bromide content in 0.003% ~ 0.130% scope, content is in 0.002% ~ 0.130% scope for Glycopyrronium Bromide for impurity Iz, and the Glycopyrronium Bromide bulk drug with these features is that the present invention is preferred.
composition example 1:
Use the embodiment of the present invention 1 step (4) gained Glycopyrronium Bromide as bulk drug, (formula is listed with 1ml amount by following formulated injection liquid, but batch quantity is 1000ml during actual dosing): Glycopyrronium Bromide 0.2mg, 1N hydrochloric acid and/or 1N Sodium hydroxide q. s regulate the final ph of injection liquid to be 2.5, and water for injection adds to 1ml in right amount.
Injection liquid compound method routinely, prepares injection liquid.When dosing, optionally in injection liquid, add certain amount of impurity Iy, obtain the injection liquid with different impurities Iy content.
By these injection liquid sealings by fusing in 1ml Brown Glass Brown glass bottles and jars only, these injection liquids are sealed, place 4 months 40 DEG C of condition lower seals, lucifuges, calculate and dispose certain impurity phase after 4 months with this understanding percentage ratio is increased for the content of this impurity 0 month time.
Found that, in various content situation, impurity Ix and impurity Iy increased percentage ratio all lower than 51% relative to its content 0 month time 6 months time.Such as embodiment 1 step (4) for raw material does not add the injection liquid of impurity Iy, impurity Ix was 0.024% 0 month time, was 0.031% when June, and it is 29% that impurity Ix content increases percentage ratio; Impurity Iy was 0.021% 0 month time, was 0.028% when June, and it is 33% that impurity Iy content increases percentage ratio.
But for impurity Iz, it increases percentage ratio at the content of high-temperature treatment after 4 months and but shows relevant with impurity Iy content in sample: when impurity Iy content lower than 0.300% time, impurity Iz content increases percentage ratio all lower than 45%; But when impurity Iy content is greater than 0.300%, impurity Iz content increases percentage ratio display and is increased to more than 90%, and in sample, impurity Iy content higher then impurity Iz content increase percentage ratio is larger.Concrete outcome is in table 5.
Table 5:
No. Injection liquid (the main batching of interpolation) Feature (0 month Ix, Iy, Iz% content) April, Iz increased percentage ratio
1 Ex1S(4) Ix=0.024、Iy=0.021、Iz=0.014 25%
2 Ex1S(4)+Iy Ix=0.025、Iy=0.050、Iz=0.013 18%
3 Ex1S(4)+Iy Ix=0.024、Iy=0.100、Iz=0.014 25%
4 Ex1S(4)+Iy Ix=0.024、Iy=0.150、Iz=0.015 32%
5 Ex1S(4)+Iy Ix=0.023、Iy=0.200、Iz=0.015 30%
6 Ex1S(4)+Iy Ix=0.026、Iy=0.250、Iz=0.014 37%
7 Ex1S(4)+Iy Ix=0.025、Iy=0.300、Iz=0.014 39%
8 Ex1S(4)+Iy Ix=0.024、Iy=0.350、Iz=0.015 97%
9 Ex1S(4)+Iy Ix=0.024、Iy=0.400、Iz=0.014 173%
10 Ex1S(4)+Iy Ix=0.025、Iy=0.500、Iz=0.014 288%
11 Ex1S(4)+Iy Ix=0.024、Iy=0.750、Iz=0.015 >300%
12 Ex1S(4)+Iy Ix=0.025、Iy=1.000、Iz=0.014 >400%
13 Ex1S(4)+Iy Ix=0.023、Iy=1.500、Iz=0.015 >500%
composition example 2:
Reference group compound example 1 is carried out, and different is only in injection liquid, supplement the phenylcarbinol increasing 9mg/ml concentration.Carry out 40 DEG C of April according to the method in composition example 1 and dispose test equally, result impurity Ix and impurity Iy increased percentage ratio all lower than 47% relative to its content 0 month time 4 months time.Such as, but impurity Iz increased the assembly thing result substantially identical (being all no more than 7 percentage points) of percentage ratio and impurity Iy content corresponding in table 54 months time relative to its content 0 month time, it is 168% that the Iz of corresponding to the sample of table 5 numbering 9 injection liquid increases percentage ratio.
composition example 3:
Reference group compound example 1 is carried out, and different is only change embodiment 1 step (4) the gained Glycopyrronium Bromide bulk drug used into embodiment 3 step (3) gained Glycopyrronium Bromide bulk drug when throwing.Carry out 40 DEG C of April according to the method in composition example 1 and dispose test equally, result impurity Ix and impurity Iy increased percentage ratio all lower than 53% relative to its content 0 month time 4 months time.Such as, but impurity Iz increased the assembly thing result substantially identical (being all no more than 5 percentage points) of percentage ratio and impurity Iy content corresponding in table 54 months time relative to its content 0 month time, it is 38% that the Iz of corresponding to the sample of table 5 numbering 7 injection liquid increases percentage ratio.
composition example 4:
Bulk drug: use foregoing embodiments 1 step (5) product, preparation example 1 impurity in products Ix, preparation example 1 impurity in products Iy and commercially available gained impurity Iz, they are carried out mixture, obtain the bulk drug with following foreign matter content: bulk drug 1:RRT0.89=0.005%, RRT1.14=0.003%, RRT2.68=0.002%; Bulk drug 2:RRT0.89=0.500%, RRT1.14=0.300%, RRT2.68=0.400%; Bulk drug 3:RRT0.89=0.250%, RRT1.14=0.150%, RRT2.68=0.200%; Bulk drug 4:RRT0.89=0.450%, RRT1.14=0.185%, RRT2.68=0.330%; Bulk drug 5:RRT0.89=0.224%, RRT1.14=0.125%, RRT2.68=0.255%.
Reference group compound example 1 is carried out, different is only change embodiment 1 step (4) the gained Glycopyrronium Bromide bulk drug used into above bulk drug 1, bulk drug 2, bulk drug 3, bulk drug 4, bulk drug 5 when throwing, obtaining 5 batches of compositions, is Glycopyrronium bromide injection.Carry out 40 DEG C of April according to the method in composition example 1 equally to these Glycopyrronium bromide injection and dispose test, result impurity Ix, impurity Iy, impurity Iz three increased percentage ratio all lower than 48% relative to its content 0 month time 4 months time.
Reference group compound example 2 is carried out, different is only change embodiment 1 step (4) the gained Glycopyrronium Bromide bulk drug used into above bulk drug 1, bulk drug 2, bulk drug 3, bulk drug 4, bulk drug 5 when throwing, obtaining 5 batches of compositions, is Glycopyrronium bromide injection.Carry out 40 DEG C of April according to the method in composition example 1 equally to these Glycopyrronium bromide injection and dispose test, result impurity Ix, impurity Iy, impurity Iz three increased percentage ratio all lower than 45% relative to its content 0 month time 4 months time.
These compositions after tested above, and what wherein impurity Iy content was minimum is 0.003%, and what impurity Iz content was minimum is 0.002%.Obviously, with regard to the present composition, wherein impurity Iy for Glycopyrronium Bromide content (such as lower than 0.50%, lower than 0.4%, lower than 0.3%) is useful lower than 0.75%, such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.750% scope (such as in 0.003% ~ 0.500% scope, such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope) be useful.
What these were prepared above can be used as preparation particularly injection liquid Glycopyrronium Bromide composition after tested, the sample that wherein impurity Ix content is minimum is 0.005%, and the sample that impurity Iy content is minimum is 0.003%, and the sample that impurity Iz content is minimum is 0.002%.Obviously, with regard to the present composition, wherein impurity Iy for Glycopyrronium Bromide content (such as lower than 0.50%, lower than 0.4%, lower than 0.3%) is useful lower than 0.75%, such as Iy foreign matter content (relative to Glycopyrronium Bromide meter) in 0.003% ~ 0.750% scope (such as in 0.003% ~ 0.500% scope, such as in 0.003% ~ 0.400% scope, such as in 0.003% ~ 0.300% scope) be useful.After tested above-mentioned can be used as preparation particularly injection liquid Glycopyrronium Bromide composition for their impurity Iy for Glycopyrronium Bromide content lower than 0.300% sample, their impurity Ix for Glycopyrronium Bromide content all lower than 0.5%, their impurity Iz for Glycopyrronium Bromide content all lower than 0.400%.---namely for can be used as Glycopyrronium Bromide composition of the present invention, as one embodiment of the invention, in Glycopyrronium Bromide composition of the present invention, impurity Ix for Glycopyrronium Bromide content in 0.005% ~ 0.500% scope, impurity Iy for Glycopyrronium Bromide content in 0.003% ~ 0.300% scope, content is in 0.002% ~ 0.400% scope for Glycopyrronium Bromide for impurity Iz, and the Glycopyrronium Bromide composition with these features is that the present invention is preferred.
test example 3: biological test
This test example investigates related substances to the impact of the neutrophil leucocyte in mouse blood.
(1) animal: BALB/c mouse, female 6 ~ 8 week age.
(2) reagent: use the embodiment of the present invention 1 step (5) gained Glycopyrronium Bromide reference substance, preparation example 1 gained impurity Ix, preparation example 2 gained impurity Iy, commercially available impurity Iz, their mixed thing to test, use 0.9% normal saline to become the sterile solution of suitable concentration.
(3) divide into groups: mouse random packet, often organize 10; Concrete group is as follows: a) control group: injection and the isopyknic physiological saline of each administration group; B) Glycopyrronium Bromide group: embodiment 1 step (5) gained Glycopyrronium Bromide reference substance; C) impurity Ix group; D) impurity Iy group; E) impurity Iz group; F) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 0.230% and the Glycopyrronium Bromide of surplus); G) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 0.400% and the Glycopyrronium Bromide of surplus); H) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 0.750% and the Glycopyrronium Bromide of surplus); I) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 1.50% and the Glycopyrronium Bromide of surplus); J) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 5.0% and the Glycopyrronium Bromide of surplus); K) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 10.0% and the Glycopyrronium Bromide of surplus); L) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 25.0% and the Glycopyrronium Bromide of surplus); M) Glycopyrronium Bromide/impurity Iz mixture group (containing the Iz of 50.0% and the Glycopyrronium Bromide of surplus).
(4) dosage, administration, method: each animal is at least raised 48 hours before administration, in-24 hours, 0 little eye socket constantly gets blood, cell counting (the routine blood test automatic analyser using Coulter company of the U.S. to produce measures) centering granulocyte count routinely, (this average is abbreviated as PNG following in the neutrophil leucocyte number average of each time point to calculate every treated animal, this average of 0 hour can be abbreviated as PNG0), for every treated animal, within-24 hours, to differ with the PNG of 0 hour two time point and be no more than 3%.Each group of reagent 3 times are given through abdominal injection respectively at 0 hour, 24 hours, 48 hours, give total compound amount (with Glycopyrronium Bromide, impurity Ix, impurity Iy, impurity Iz or its summation meter) 50 μm of ol/kg the weight of animals at every turn, such as m) Glycopyrronium Bromide/impurity Iz mixture group, the dosage of summation meter 50 μm of ol/kg the weight of animals of Iz and Glycopyrronium Bromide.The 54th hour (namely after last administration 6 hours) each animal eye socket get blood, cell counting centering granulocyte count routinely, calculate every treated animal in the 54th little neutrophil leucocyte number average (this average is abbreviated as PNG56) constantly.
(5) result calculates: the neutrophil leucocyte relative number being calculated as follows every treated animal:
Neutrophil leucocyte relative number (%)=(PNG56 ÷ PNG0) × 100%
The changing conditions of neutrophil leucocyte in above neutrophil leucocyte relative number reflection peripheral blood, this parameter is more less close to the 100% neutrophil leucocyte change shown in blood, this parameter lower than 100% time, numerical value is lower, shows that Neutrophilic granulocytopenia is more, shows that neutrophil leucocyte increases when this parameter is greater than 100%.The results are shown in Table 6.
Table 6:
Group Neutrophil leucocyte relative number Group Neutrophil leucocyte relative number
A) control group 102.5% H) Glycopyrronium Bromide/impurity Iz mixture group 57.5%
B) Glycopyrronium Bromide group 99.4% I) Glycopyrronium Bromide/impurity Iz mixture group 38.6%
C) impurity Ix group 103.3% J) Glycopyrronium Bromide/impurity Iz mixture group 23.1%
D) impurity Iy group 101.7% K) Glycopyrronium Bromide/impurity Iz mixture group 15.3%
E) impurity Iz group; 1.55% L) Glycopyrronium Bromide/impurity Iz mixture group 7.9%
F) Glycopyrronium Bromide/impurity Iz mixture group 99.5% M) Glycopyrronium Bromide/impurity Iz mixture group 2.1%
G) Glycopyrronium Bromide/impurity Iz mixture group 94.7%
For e) group, neutrophil count, by the 0th little 4530/μ L constantly, is reduced to the 54th little 70/μ L constantly.For Iz content lower than 0.4% assembly thing, neutrophil leucocyte base in blood does not originally change, but when Iz content is more than or equal to 0.75%, the neutrophil leucocyte number in blood sharply reduces, this for experimenter maintain normal body function particularly normal immunologic function be totally unfavorable.
test example 4: biological test
According to the document (B.V.Frankoetal. of the people such as B.V.Franko, Toxicol.Appl.Pharmacol.17,361 (1970)) method recorded in, measure the gained Glycopyrronium Bromide of the embodiment of the present invention 1 step (4) and medium lethal dose (the LD50 value of impurity Iz, mouse, i.p. administration, 72hr), to investigate the acute toxicity of related substances to mouse.The LD50=136mg/kg of result Glycopyrronium Bromide, the LD50=17mg/kg of impurity Iz, the security of display impurity Iz is poor more than Glycopyrronium Bromide.
industrial applicability
Glycopyrronium Bromide bulk drug provided by the invention or preparation, as a kind of anticholinergic, can be used for anesthesia, peptide ulceration, salivation etc. clinically.This bulk drug or preparation have suppression gastric secretion and regulate gastrointestinal peristalsis effect; There is the anti-salivation effect stronger than coromegine, but do not have central cholinolytic active.Be generally used for the diseases such as gastric and duodenal ulcer, chronic gastritis, gastroxia clinically.

Claims (36)

1. a bulk drug for hyoscine, the activeconstituents of this bulk drug be Glycopyrronium Bromide namely with compounds of Formula I:
(formula I)
And enantiomorph; The following formula I y impurity as impurity is also comprised in this bulk drug:
(formula Iy);
Described Iy impurity phase for Glycopyrronium Bromide content in 0.003% ~ 0.130% scope.
2. bulk drug according to claim 1, comprising as the formula I of main ingredient and enantiomorph thereof, and optional as impurity with following formula Ix impurity:
(formula Ix)
And enantiomorph.
3. bulk drug according to claim 2, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.5%.
4. bulk drug according to claim 2, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.4%.
5. bulk drug according to claim 2, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.3%.
6. bulk drug according to claim 1, comprising as the formula I of main ingredient and enantiomorph thereof, and optional as impurity with following formula Iz impurity:
(formula Iz).
7. bulk drug according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.50%.
8. bulk drug according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.30%.
9. bulk drug according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.25%.
10. bulk drug according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.20%.
11. bulk drugs according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.15%.
12. bulk drugs according to claim 6, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.13%.
13. according to the bulk drug of any one of claim 1-12, it places 6 months 40 ° of C condition lower seals, lucifuges, after 6 months, certain impurity phase is for content increase percentage ratio when 0 month to calculate disposal with this understanding, and wherein impurity Iz content increases percentage ratio lower than 50%.
14. bulk drugs according to claim 13, wherein impurity Iz content increases percentage ratio lower than 40%.
15. 1 kinds of pharmaceutical compositions, wherein comprise the bulk drug described in any one of claim 1-14, and optional pharmaceutically acceptable carrier or auxiliary material.
16. pharmaceutical compositions according to claim 15, it is oral preparations or injection formulations.
17. pharmaceutical compositions according to claim 15, it is tablet, capsule, granule, injection liquid, lyophilize powder injection, suspensoid or pill.
18. pharmaceutical compositions according to claim 15, it is injection liquid, comprises in the every 1ml of this injection liquid: the Glycopyrronium Bromide of 0.1 ~ 0.5mg, acid-base modifier are in right amount to regulate the pH value of injection liquid in 2.0 ~ 3.0 scopes and to add to the water for injection of full dose.
19. pharmaceutical compositions according to claim 19, wherein also comprise phenylcarbinol.
20. pharmaceutical compositions according to claim 19, the Benzyl alcohol concentrations in this injection liquid is 0.5 ~ 1.5mg/ml.
21. pharmaceutical compositions according to claim 19, the Benzyl alcohol concentrations in this injection liquid is 0.7 ~ 1.2mg/ml.
22. pharmaceutical compositions according to claim 19, the Benzyl alcohol concentrations in this injection liquid is 0.8 ~ 1.0mg/ml.
23. pharmaceutical compositions according to claim 19, the Benzyl alcohol concentrations in this injection liquid is 0.9mg/ml.
24. pharmaceutical compositions according to claim 15, it is lyophilize powder injection, comprises in this powder injection: the Glycopyrronium Bromide of 0.2 weight part, the freeze-dried excipient of 20 ~ 400 weight parts.
25. pharmaceutical compositions according to claim 15, it is lyophilize powder injection, comprises in this powder injection: the Glycopyrronium Bromide of 0.2 weight part, the freeze-dried excipient of 20 ~ 400 weight parts, optional pH adjusting agent in right amount with make this powder injection water for injection be diluted to pH value that Glycopyrronium Bromide concentration is solution during 0.2mg/ml in 2.0 ~ 3.0 scopes.
26. according to claim 15 to the pharmaceutical composition of 25 any one, comprising the Glycopyrronium Bromide as active ingredient, and as the Ix impurity of impurity; Wherein Ix impurity phase for Glycopyrronium Bromide content lower than 1.0%.
27. pharmaceutical compositions according to claim 26, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.75%.
28. pharmaceutical compositions according to claim 26, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.5%.
29. pharmaceutical compositions according to claim 26, wherein Ix impurity phase for Glycopyrronium Bromide content lower than 0.4%.
30. according to claim 15 to the pharmaceutical composition of 25 any one, comprising the Glycopyrronium Bromide as active ingredient, and as the Iy impurity of impurity; Wherein Iy impurity phase for Glycopyrronium Bromide content in 0.003% ~ 0.300% scope.
31. according to claim 15 to the pharmaceutical composition of 25 any one, comprising the Glycopyrronium Bromide as active ingredient, and as the Iz impurity of impurity; Wherein Iz impurity phase for Glycopyrronium Bromide content lower than 1.00%.
32. according to the pharmaceutical composition of claim 31, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.75%.
33. according to the pharmaceutical composition of claim 31, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.50%.
34. according to the pharmaceutical composition of claim 31, wherein Iz impurity phase for Glycopyrronium Bromide content lower than 0.4%.
35. according to claim 15 to the pharmaceutical composition of 25 any one, it places 4 months 40 ° of C condition lower seals, lucifuges, after 4 months, certain impurity phase is for content increase percentage ratio when 0 month to calculate disposal with this understanding, and wherein impurity Iz content increases percentage ratio lower than 50%.
36. according to the pharmaceutical composition of claim 34, and wherein impurity Iz content increases percentage ratio lower than 40%.
CN201310571655.XA 2013-11-13 2013-11-13 Anticholinergic pharmaceutical composition Active CN103553996B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510727148.XA CN105175304A (en) 2013-11-13 2013-11-13 Cholinolytic drug glycopyrronium bromide and composition
CN201310571655.XA CN103553996B (en) 2013-11-13 2013-11-13 Anticholinergic pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310571655.XA CN103553996B (en) 2013-11-13 2013-11-13 Anticholinergic pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510727148.XA Division CN105175304A (en) 2013-11-13 2013-11-13 Cholinolytic drug glycopyrronium bromide and composition

Publications (2)

Publication Number Publication Date
CN103553996A CN103553996A (en) 2014-02-05
CN103553996B true CN103553996B (en) 2016-01-20

Family

ID=50008404

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310571655.XA Active CN103553996B (en) 2013-11-13 2013-11-13 Anticholinergic pharmaceutical composition
CN201510727148.XA Pending CN105175304A (en) 2013-11-13 2013-11-13 Cholinolytic drug glycopyrronium bromide and composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510727148.XA Pending CN105175304A (en) 2013-11-13 2013-11-13 Cholinolytic drug glycopyrronium bromide and composition

Country Status (1)

Country Link
CN (2) CN103553996B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105362218A (en) * 2015-12-17 2016-03-02 浙江华海药业股份有限公司 Glycopyrronium bromide injection and preparation method thereof
CN107345945B (en) * 2016-05-05 2019-12-17 辽宁药联制药有限公司 High performance liquid chromatography method for resolving glycopyrronium bromide enantiomer and checking impurities
CN108976114A (en) * 2017-06-05 2018-12-11 上海奥博生物医药技术有限公司 A kind of purification process of glycopyrronium bromide intermediate 2- cyclopenta -2-Hydroxyphenyl Acetic Acid
CN111437254B (en) * 2020-05-28 2022-05-03 成都欣捷高新技术开发股份有限公司 Glycopyrronium bromide injection and preparation method thereof
CN114428131B (en) * 2021-12-27 2023-09-15 山东泰合医药科技有限公司 Detection method for resolving diastereoisomers of glycopyrronium bromide intermediate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133021A (en) * 2005-03-03 2008-02-27 索塞R&D有限公司 Crystallisation and purification of glycopyrronium bromide
CN102388021A (en) * 2009-04-09 2012-03-21 诺瓦提斯公司 Process for preparing pyrrolidinium salts
CN103012231A (en) * 2012-12-14 2013-04-03 沈阳药科大学 Preparation method and application of glycopyrronium bromide chiral antipode

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5186141B2 (en) * 2007-06-29 2013-04-17 ユニ・チャーム株式会社 Animal excrement disposal sheet
CN103159659A (en) * 2011-12-19 2013-06-19 沈阳药科大学 Preparation method of muscarinic receptor antagonist glycopyrronium bromide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133021A (en) * 2005-03-03 2008-02-27 索塞R&D有限公司 Crystallisation and purification of glycopyrronium bromide
CN102388021A (en) * 2009-04-09 2012-03-21 诺瓦提斯公司 Process for preparing pyrrolidinium salts
CN103012231A (en) * 2012-12-14 2013-04-03 沈阳药科大学 Preparation method and application of glycopyrronium bromide chiral antipode

Also Published As

Publication number Publication date
CN105175304A (en) 2015-12-23
CN103553996A (en) 2014-02-05

Similar Documents

Publication Publication Date Title
USRE49110E1 (en) Pharmaceutical formulations containing dopamine receptor ligands
CN103553996B (en) Anticholinergic pharmaceutical composition
JP6527290B2 (en) Application of dextrorotatory oxiracetam in the pharmaceutical field
IL207400A (en) Composition comprising degarelix for use in the treatment of prostate cancer
WO2004054574A1 (en) Solid drug for oral use
EA029478B1 (en) Stable solutions of combined active pharmaceutical ingredients for oral administration
WO2021150885A1 (en) Cannabinoid derivatives
EA027869B1 (en) Stabilized tacrolimus composition
BRPI0719236A2 (en) FENILALKYL CARBAMATE COMPOSITIONS
CN103709170A (en) Medicinal crude drug for reducing blood sugar
US20210322438A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN104447771A (en) Stable asenapine maleate sublingual compound
CN104447770A (en) Asenapine compound
CN103694245A (en) Crude medicine for hypoglycemic medicine
US20190008868A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
US20190388428A1 (en) A Pharmaceutical Composition Comprising An Oxazine Derivative And Its Use In The Treatment Or Prevention Of Alzheimer's Disease
CN103483352A (en) Medicinal bulk drug for resisting tumors
CN103641764B (en) The pharmaceutical composition of adjusting blood lipid
CN104072400A (en) Oxiracetam compound and pharmaceutical composition thereof
US20080063704A1 (en) Stable gabapentin compositions
JP6538976B2 (en) Compound PAC-1 or a salt thereof and a pharmaceutical composition containing them
CN101676290A (en) Levofloxacin salt, and preparation method thereof and medicament composition
CN107648195A (en) Stable Febustat capsule medicine composition
CN107737105A (en) A kind of nasal cavity agent of azelastine hydrochloride composition spray and production technology
CN105030728A (en) Medicinal atorvastatin calcium composition capsules for treating coronary heart disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151117

Address after: 100079 Beijing Fengtai District City Jia Garden No. 15, No. 7 floor West

Applicant after: Beijing Sanquan Pharmaceutical Technology Co.,Ltd.

Address before: 061000 Hebei city of Cangzhou province Xing Qi town No. 300

Applicant before: Li Xinghui

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20181012

Address after: 415001 Dongting pharmaceutical company, 375 de Shan Avenue, Changde economic and Technological Development Zone, Changde, Hunan

Patentee after: Hunan Dongting Pharmaceutical Co., Ltd.

Address before: 100079 west side of building 7, building 15, Jia Jia garden, Fengtai District, Beijing.

Patentee before: Beijing Sanquan Pharmaceutical Technology Co.,Ltd.